

The molecular mechanisms of pancreatic β -cell glucotoxicity: recent findings and future research directions

Mohammed Bensellam^{1,2}, D. Ross Laybutt², and Jean-Christophe Jonas^{1,#}

¹ Université catholique de Louvain, Institut de recherche expérimentale et clinique, Pôle d'endocrinologie, diabète et nutrition, Brussels, Belgium; ²Diabetes and Obesity Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia;

[#] To whom correspondence should be addressed (Avenue Hippocrate 55 (B1.55.06), B-1200 Brussels, Belgium; email: jean-christophe.jonas@uclouvain.be)

Abstract

It is well established that regular physiological stimulation by glucose plays a crucial role in the maintenance of the β -cell differentiated phenotype. In contrast, prolonged or repeated exposure to elevated glucose concentrations both *in vitro* and *in vivo* exerts deleterious or toxic effects on the β -cell phenotype, a concept termed as glucotoxicity.

Evidence indicates that the latter may greatly contribute to the pathogenesis of type 2 diabetes. Through the activation of several mechanisms and signaling pathways, high glucose levels exert deleterious effects on β -cell function and survival and thereby, lead to the worsening of the disease over time. While the role of high glucose-induced β -cell overstimulation, oxidative stress, excessive Unfolded Protein Response (UPR) activation, and loss of differentiation in the alteration of the β -cell phenotype is well ascertained, at least *in vitro* and in animal models of type 2 diabetes, the role of other mechanisms such as inflammation, O-GlcNacylation, PKC activation, and amyloidogenesis requires further confirmation. On the other hand, protein glycation is an emerging mechanism that may play an important role in the glucotoxic deterioration of the β -cell phenotype. Finally, our recent evidence suggests that hypoxia may also be a new mechanism of β -cell glucotoxicity.

Deciphering these molecular mechanisms of β -cell glucotoxicity is a mandatory first step toward the development of therapeutic strategies to protect β -cells and improve the functional β -cell mass in type 2 diabetes.

227 words in the abstract, 8636 words in body text, 394 references, 5 figures, 3 tables.

Contents

1-	INTRODUCTION.....	3
2-	PHYSIOLOGICAL EFFECTS OF GLUCOSE AND OTHER NUTRIENTS ON THE β-CELL DIFFERENTIATED PHENOTYPE	4
2-1	SHORT-TERM EFFECTS	4
2-2	LONG-TERM EFFECTS	5
3-	DELETERIOUS EFFECTS OF SUPRA-PHYSIOLOGICAL GLUCOSE STIMULATION ON THE β-CELL DIFFERENTIATED PHENOTYPE.....	7
3-1	THE CONCEPT OF GLUCOTOXICITY.....	7
3-2	THE MECHANISMS OF β -CELL GLUCOTOXICITY	9
3-2-1	<i>β-cell overstimulation.....</i>	<i>10</i>
3-2-2	<i>Oxidative stress</i>	<i>11</i>
3-2-3	<i>ER stress.....</i>	<i>14</i>
3-2-4	<i>Protein glycation and AGE-receptors.....</i>	<i>17</i>
3-2-5	<i>Hexosamine pathway.....</i>	<i>18</i>
3-2-6	<i>PKC activation.....</i>	<i>19</i>
3-2-7	<i>Inflammation</i>	<i>19</i>
3-2-8	<i>Islet amyloid deposition</i>	<i>21</i>
3-2-9	<i>Hypoxia</i>	<i>22</i>
3-2-10	<i>Alteration of the β-cell differentiated phenotype.....</i>	<i>24</i>
4-	FUTURE RESEARCH DIRECTIONS.....	27
5-	CONCLUSION.....	29

1- Introduction

Pancreatic β -cells secrete insulin after meals to tighten blood glucose levels within a narrow range. The regulation of their function relies on a complex array of metabolic, neural, and hormonal factors. The most important factor is glucose itself, since most of the other modulators of insulin release exert their effects only in the presence of stimulatory levels of glucose. Thus, the rise in plasma glucose concentration triggers its rapid equilibrium across β -cell plasma membrane, its oxidation by glycolysis and the Krebs cycle, and an increase in the cytosolic ATP/ADP ratio. The latter event leads to the closure of ATP-sensitive K^+ (K_{ATP}) channels, plasma membrane depolarization, and opening of voltage-dependent Ca^{2+} channels. The ensuing Ca^{2+} influx induces a rise in cytosolic free Ca^{2+} concentration ($[Ca^{2+}]_i$) which is the triggering signal for insulin secretion. This sequence of events is called the triggering pathway of glucose-stimulated insulin secretion (GSIS) (Henquin, 2000; Henquin et al., 2003). On the other hand, coupling factors produced by glucose metabolism, hormones, and neurotransmitters can amplify Ca^{2+} -induced insulin granule exocytosis. It is called the amplifying pathway of insulin secretion (Henquin, 2000; Henquin et al., 2003; Jitrapakdee et al., 2010; MacDonald et al., 2005).

The ability of β -cells to respond to an acute glucose challenge depends on the adequate level of expression of several genes, including preproinsulin, the glucose transporter *Glut2*, glucokinase (*Gck*), etc. (Schuit et al., 2002). This level of expression is modulated by meals: it is reduced during fasting and rapidly restored upon feeding (Hinke et al., 2004). Interestingly, both chronic hypoglycaemia and chronic hyperglycemia induce the loss of β -cell differentiation, alter the stimulus-secretion coupling, and increase the rate of β -cell apoptosis, along with increased expression of genes under-expressed in normal β -cells (Blume et al., 1995; Butler et al., 2003; Iwashima et al., 1994; Jonas et al., 1999; Laybutt et al., 2002b). Similarly, *in vitro*, rodent β -cell function and survival are optimally preserved by culture in the presence of 10 mM glucose (G10) and markedly impaired by culture in either lower (G2-G5) or higher (G30) glucose concentrations (Bensellam et al., 2009; Efanova et al., 1998; Khaldi et al., 2004). It seems therefore that glucose stimulation exerts beneficial effects on the β -cell phenotype between G2 and G10 (**Figure 1**). In contrast, supraphysiological glucose concentrations (between G10 and G30) are deleterious for β -cell function and survival, a concept termed as glucotoxicity (**Figure 1**). The latter plays an important role in the alteration of the functional β -cell mass in type 2 diabetes (T2D), and contributes to the progressive

worsening of glucose intolerance in these patients (Buchanan, 2003; Chang-Chen et al., 2008; Weir et al., 2009).

Rigorous investigation since the 80's led to a progressive understanding of the molecular pathways that may underlie β -cell glucotoxicity. However, these mechanisms are not fully understood and some of them are debated. In this extensive review, we briefly emphasize the importance of regular physiological stimulation by nutrients in preserving the functional β -cell mass, and discuss the concept of β -cell glucotoxicity. We describe in details our current knowledge regarding the activation of these pathways by chronic hyperglycemia, how does each pathway contribute to the alteration of the β -cell phenotype, and their complex interaction. Finally, we present the future research directions raised by these findings and highlight unsettled questions in the field.

2- Physiological effects of glucose and other nutrients on the β -cell differentiated phenotype

Regular stimulation by nutrients plays a key role in maintaining the functional β -cell mass through effects on β -cell survival and gene expression. The latter effects, which maintain β -cells in their differentiated state, include increased expression of “ β -cell enriched genes” and repression of so-called “ β -cell forbidden genes” (Quintens et al., 2008; Schuit et al., 2002). Physiological glucose stimulation differently affects the β -cell phenotype depending on the duration of the stimulation (**Figure 1**).

2-1 Short-term effects

In the short-term (from minutes to a few hours), in addition to GSIS, glucose and other nutrients stimulate protein synthesis with a preferential effect on proinsulin and other granule proteins (Alarcon et al., 1993; Ashcroft et al., 1980; Grimaldi et al., 1987; Guest et al., 1989; Ling et al., 1996; Schuit et al., 1988; Skelly et al., 1996) (**Figure 1**). Glucose regulates proinsulin biosynthesis predominantly by rapid stimulation of pre-existing preproinsulin mRNA translation (Gilligan et al., 1996; Gomez et al., 2004; Greenman et al., 2005; Itoh et al., 1978; Itoh and Okamoto, 1980; Vander Mierde et al., 2007; Welsh et al., 1986; Wicksteed et al., 2001). Similarly to GSIS, proinsulin biosynthesis requires glucose metabolism but is independent from changes in $[Ca^{2+}]_i$ (Alarcon et al., 2002; Ashcroft et al., 1980; Leibowitz et al., 2003; Wicksteed et al., 2003).

In addition, glucose has been shown to induce acutely rapid changes in the polysomal mRNA levels of several genes including those involved in oxidative stress response and endoplasmic reticulum (ER) stress response (Greenman et al., 2007).

In parallel, it is well established that the acceleration of β -cell metabolism upon acute glucose stimulation increases Ca^{2+} pumping into the ER via the sarcoendoplasmic reticulum Ca^{2+} -ATPase 2B (Moore et al., 2011; Ravier et al., 2011; Tengholm et al., 1999; Varadi and Rutter, 2002) (**Figure 1**). Noteworthy, the ER Ca^{2+} concentration ($[\text{Ca}^{2+}]_{\text{ER}}$) plays a key role in proper function of several ER-resident molecular chaperones and foldases (Corbett et al., 1999; Gelebart et al., 2005; Suzuki et al., 1991), and in the processing of proinsulin (Guest et al., 1997). Therefore, this event may play a role in the modulation of chaperones activity, and in the adaptation of the ER folding machinery to the important increase in protein synthetic load triggered by glucose stimulation in β -cells (Ling and Pipeleers, 1996; Schuit et al., 1988).

These short-term effects are essential in refilling insulin cellular stores, maintaining β -cell glucose-responsiveness, and preparing β -cells for the next glucose challenge *in vivo* (Hinke et al., 2004).

2-2 Long-term effects

Besides the acute regulatory mechanisms, the maintenance of β -cell glucose responsiveness in the long-term (more than 12h) relies on an adequate level of gene expression (**Figure 1**). Indeed, it has been shown that extended physiological glucose stimulation regulates insulin gene transcription (Nielsen et al., 1985; Van Lommel et al., 2006; Wicksteed et al., 2003), translation (Permutt, 1974; Schuit et al., 1988; Wicksteed et al., 2003), preRNA splicing (Wang et al., 1997), and mRNA stabilization (Tillmar et al., 2002; Welsh et al., 1985). The glucose-dependent regulation of insulin gene expression relies on a network of transcription factors that include principally pancreas duodenum homeobox-1 (PDX-1), V-maf musculoaponeurotic fibrosarcoma oncogene homologue A (MafA), and neurogenic differentiation 1 (NeuroD1). Glucose modulates the activity of these transcription factors through transcriptional/posttranslational mechanisms that have been reviewed elsewhere (Andrali et al., 2008).

In addition to the insulin gene, prolonged stimulation (24h) of purified primary rat β -cells within the physiological range of glucose concentrations (G10 vs. G3) has been shown to increase the mRNA levels of genes encoding proteins of several components of the triggering pathway of insulin secretion, including *Glut2*, subunits of the mitochondrial respiratory chain, both subunits of the K_{ATP} channel, genes involved in cataplerosis, fatty acid biosynthesis, and

cholesterol biosynthesis (Flamez et al., 2002). Our previous microarray study testing the effects of 18h culture in increasing glucose concentrations (G2, G5, G10 and G30) on the transcriptome of rat islets largely confirmed and extended these observations (Bensellam et al., 2009). In agreement, rat β -cells exposed to low glucose concentrations *in vivo* during prolonged fasting (72h) showed a marked decrease in the mRNA levels of *Glut2*, voltage-dependent L-type Ca^{2+} channel $\alpha 1$ subunit, insulin, and *Gck* mRNA levels. These alterations were rapidly reversed following refeeding (Iwashima et al., 1994).

On the other hand, culture of rat and mouse islets in G10 vs. G2-G5 strongly inhibited the expression of several stress-response genes (**Figure 1**), including oxidative stress response genes such as heme-oxygenase 1 (*Hmox1*) and metallothionein 1a (*Mt1a*), ER stress response genes such as heat shock 70kDa protein 5 (*Hspa5/BiP*), DNA-damage inducible transcript 3 (*Ddit3* (*Chop/Gadd153*)), growth arrest and DNA-damage-inducible protein 34 (*Gadd34*), activating transcription factor 3 (*Atf3*) and tribbles homologue 3 (*Trb3*), and pro-apoptotic genes such as the proto-oncogene myelocytomatosis viral oncogene homolog (avian) (*Myc*) (Bensellam et al., 2009; Elouil et al., 2007; Jonas et al., 2009). Remarkably, these effects are accompanied by acute inhibition of mitochondrial oxidative stress (Hou et al., 2008a; Martens et al., 2005; Roma et al., 2012; Sarre et al., 2012).

In parallel to gene expression changes, physiological glucose stimulation is crucial for the preservation of optimal β -cell function. Thus, prolonged culture of primary rat β -cells, rat islets, and human islets in the presence of low non-stimulatory glucose concentrations noticeably decreased glucose-induced rise in $[\text{Ca}^{2+}]_i$, GSIS, and insulin biosynthesis (Bensellam et al., 2009; Flamez et al., 2002; Ling and Pipeleers, 1996). Similarly, islets of fasted rats (72h) exhibited alterations of β -cell function that were reversed after refeeding (Iwashima et al., 1994).

Moreover, glucose is one of the most important stimuli for β -cell mass maintenance by stimulating proliferation-neogenesis-hypertrophy (Alonso et al., 2007; Bernard et al., 1999; Bonner-Weir et al., 1989; De Vroede et al., 1990; Hugl et al., 1998; Jetton et al., 2008; Kwon et al., 2006; Liu et al., 2009; Maedler et al., 2006; Steil et al., 2001; Swenne, 1982; Topp et al., 2004; Tyrberg et al., 1996) and inhibiting apoptosis (Bensellam et al., 2009; Costes et al., 2006; Efanova et al., 1998; Hoorens et al., 1996; Ling et al., 1994; Srinivasan et al., 2002; Van de Casteele et al., 2003) (**Figure 1**).

3- Deleterious effects of supra-physiological glucose stimulation on the β -cell differentiated phenotype

3-1 The concept of glucotoxicity

While regular physiological glucose stimulation is essential to the maintenance of the β -cell differentiated phenotype as explained in the previous section, prolonged or repeated exposure to elevated glucose concentrations both *in vitro* and *in vivo* exerts toxic effects on the β -cell phenotype (Unger and Grundy, 1985) (**Figure 1**). Thus, in the context of T2D, the inability of β -cells to adapt to the high organism's metabolic demand by secreting adequate amounts of insulin leads to the development of hyperglycemia (Beck-Nielsen and Groop, 1994; Kahn, 2003). The latter exerts additional damaging effects on β -cells, thus creating a vicious circle that contributes to the progressive decrease of the functional β -cell mass and thereby, to the worsening of the disease over time (Buchanan, 2003) (**Figure 2**).

Of note, hyperglycemia exerts its deleterious effects either directly (glucotoxicity) or by unveiling the harmful effects of fatty acids (glucolipotoxicity). Although it is well established that elevated free fatty acid (FFA) levels exert deleterious effects on β -cells *in vitro*, there is no certainty about their role in β -cell demise in T2D subjects (Boden and Shulman, 2002; Grill and Bjorklund, 2009; Weir et al., 2001). Nevertheless, growing evidence points to a permissive effect of glucose on the deleterious actions of FFAs (Poitout and Robertson, 2008). In this review, we have only focused on β -cell glucotoxicity. The role of synergistic effects of the combination high glucose-elevated FFAs has been extensively reviewed elsewhere (Poitout et al., 2010). Other reactive metabolites including ketone bodies have been shown to alter β -cell function *in vitro* (Takehiro et al., 2005; Zhou and Grill, 1995). However, their potential contribution to β -cell glucotoxicity in T2D requires further proof.

Besides its role in β -cell demise in T2D, the hyperglycemic milieu also plays an important role in the loss of β -cell mass and the deterioration of β -cell differentiation after islet transplantation (Laybutt et al., 2007a; Montana et al., 1993). It is thus important to study the phenomenon of glucotoxicity and decipher its underlying mechanisms, toward the development of therapeutic solutions to protect and/or restore the functional β -cell mass (**Figure 2**). However, despite rigorous investigations hitherto, the precise nature of these mechanisms and their contribution to the pathology of T2D is not fully understood.

The first source of confusion arises from the lack of consensus about the definition of glucotoxicity. One school of thoughts describes glucotoxicity as the irreversible alterations of

β -cell function and gene expression resulting from prolonged exposure (several months or years rather than days) to supra-physiological glucose concentrations both *in vitro* and *in vivo* (Briaud et al., 1999; Gleason et al., 2000; Harmon et al., 2001; Robertson and Harmon, 2006; Tanaka et al., 1999). These authors maintain there is a clear distinction between glucose desensitization, which connotes a temporary reversible state of β -cell refractoriness to glucose stimulation due to β -cell exhaustion after exposition to elevated glucose concentrations (several hours to several days) (Kaiser et al., 1991; Sako and Grill, 1990), and the “true” glucose toxicity (Moran et al., 1997; Robertson et al., 1994; Robertson et al., 2003). Nonetheless, one can debate this distinction between glucose desensitization and glucose toxicity.

Concerning the dimension of time, numerous early high glucose-induced stress genes, such as *Myc* and *Hmox1*, have been shown to represent early signs of β -cell glucotoxicity that can profoundly affect the β -cell fate (Jonas et al., 2001; Jonas et al., 2003; Kaneto et al., 2002a; Laybutt et al., 2002a; Laybutt et al., 2002c; Pascal et al., 2008; Van de Casteele et al., 2003). Besides, β -cell apoptosis, which represents the final stage of glucotoxicity, has been observed after culture of human and rodent islets for only several days in elevated glucose concentrations (Bensellam et al., 2009; Federici et al., 2001; Jonas et al., 2009; Khaldi et al., 2004; Leibowitz et al., 2001; Ling et al., 1994; Maedler et al., 2001; Piro et al., 2002), but also *in vivo* in animal models of T2D after few weeks of hyperglycemia, or even few days in some animal models (Donath et al., 1999; Finegood et al., 2001; Kluth et al., 2011; Leibowitz et al., 2001; Pick et al., 1998). Furthermore, it has been shown that even intermittent exposure of human islets, rat islets, and rat insulinoma cells (INS1) to high glucose concentrations for several days markedly impaired GSIS and triggered β -cell apoptosis (DelGuerra et al., 2007; Hou et al., 2008b). These observations suggest that postprandial glycemic fluctuations in prediabetic individuals with impaired glucose tolerance (IGT) may exert glucotoxic effects that contribute to the loss of functional β -cell mass and the progression toward frank diabetes (**Figure 2**). Therefore, it seems that exposure of β -cells to high glucose levels for months or years is not an obligatory criterion to define glucotoxicity, at least *in vitro* and in animal models of T2D.

We therefore consider the early defects in GSIS and the concomitant or subsequent changes in gene expression and ultimate decrease of the functional β -cell mass as manifestations of glucose toxicity, regardless of the duration of the exposure to elevated glucose levels and whether these alterations are corrected after blood glucose normalization or

not (Bensellam et al., 2009; Jonas et al., 1999; Jonas et al., 2009; Khaldi et al., 2004; Laybutt et al., 2002b).

Another source of confusion is the important discrepancy between evidences gained from *in vitro* and *in vivo* models of β -cell glucotoxicity and also between species. Such differences stem mainly from the variability of glucose concentrations at which β -cell glucotoxicity is observed. Thus, on the one hand, $\sim$ G10, which is the optimal glucose concentration for rodent β -cell function and survival *in vitro* (Bensellam et al., 2009; Efanova et al., 1998; Jonas et al., 2009), is already harmful *in vivo* (Finegood et al., 2001; Jonas et al., 1999; Laybutt et al., 2002b) as well as for cultured human islets (Maedler et al., 2001) that are best preserved by culture in the presence of $\sim$ G5 (Ling and Pipeleers, 1996). On the other hand, the very high glucose levels that induce glucotoxicity *in vitro* ($\sim$ G30-40) (Bensellam et al., 2009; Efanova et al., 1998; Jonas et al., 2009; Khaldi et al., 2004; Zraika et al., 2006) are unlikely to occur in T2D subjects (ADA, 2010). These differences between *in vitro* and *in vivo* models may result in part from the absence, *in vitro*, of other nutrients such as amino acids, incretin hormones such as GLP-1, and neurotransmitters such as acetylcholine that increase the sensitivity of β -cells to glucose, and also from the shorter periods of culture in the presence of elevated glucose concentrations that can be tested *in vitro*. Nevertheless, these differences do not disqualify totally *in vitro* studies. The latter have provided invaluable information about the role of glucotoxicity in β -cell damage, and several lines of evidence suggest that similar mechanisms of β -cell glucotoxicity are operative *in vitro* and *in vivo* (Chang-Chen et al., 2008; Jonas et al., 2009; Marchetti et al., 2010; Poitout and Robertson, 2008).

3-2 The mechanisms of β -cell glucotoxicity

Despite intensive therapy, β -cell function deteriorates during the years following the diagnosis of T2D (Turner, 1998; UKPDS, 1998), suggesting a role of the metabolic environment in β -cell demise. Therefore, persistent hyperglycemia has been proposed among the potential causes underlying these functional alterations based on earlier observations that blood glucose normalization partially reverses β -cell defects (Garvey et al., 1985; Glaser et al., 1988; Kosaka et al., 1980; Rossetti et al., 1987; Turner et al., 1976). Besides, it is now accepted that insufficient GSIS in T2D may also result from a reduction in β -cell mass (Deng et al., 2004; Rahier et al., 2008; Sakuraba et al., 2002; Yoon et al., 2003). Our current understanding of the role of glucotoxicity in the loss of functional β -cell mass is based mainly on animal studies and *in vitro* experimentation on isolated islets and β -cell lines (Grill and

Bjorklund, 2009; Jonas et al., 2009; Poitout and Robertson, 2008). Over several years, these studies revealed complex mechanisms behind β -cell glucotoxicity.

3-2-1 β -cell overstimulation

It is well established that conditions of enhanced insulin secretory demand *in vivo* (insulin resistance, IGT, and hyperglycemia), or prolonged exposure to elevated glucose levels *in vitro* lead to β -cell overstimulation until a point where insulin biosynthesis is unable to cope with the high rates of insulin secretion (**Figure 2**). This leads to the alteration of GSIS and the elevation of the circulating proinsulin to insulin ratio, likely as a consequence of β -cell insulin reserve depletion and the release of newly formed insulin granules before complete processing of proinsulin (Alarcon et al., 1995; Gadot et al., 1994; Gadot et al., 1995; Ling et al., 2001; Marshak et al., 1999; Sempoux et al., 2001).

The role of overstimulation in β -cell glucotoxicity has been clearly demonstrated by β -cell rest interventions. Thus, it has been shown that the inhibition of GSIS and the depletion of islet insulin stores induced by prior culture of rat and human islets in the presence of high glucose concentrations was prevented by addition of K_{ATP} channel openers, such as diazoxide, to the culture medium (Bjorklund and Grill, 1993; Ma et al., 2007; Ritzel et al., 2004; Song et al., 2003; Yoshikawa et al., 2004). In agreement, the alteration of GSIS triggered by 48h glucose infusion in rats was opposed by co-infusion of diazoxide (Sako and Grill, 1990). Furthermore, long-term treatment of transplanted diabetic rats with K_{ATP} channel openers has been shown to markedly preserve the function of the graft even one week after drug withdrawal (Bjorklund et al., 2004).

Besides the restoration of islet insulin stores, the beneficial effects of diazoxide have been proposed to stem, at least in part, from the improvement of β -cell survival both *in vitro* and *in vivo* (Efanova et al., 1998; Huang et al., 2007b), direct effects on mitochondria (Grimmsmann and Rustenbeck, 1998; Lenzen and Panten, 1983; MacDonald, 1981), and important gene expression changes including: (i) upregulation of *Pdx1*, NK6 transcription factor related, locus 1, and genes of fatty acid synthesis, and (ii) downregulation of cAMP Response-Element Modulator (*Crem*), lactate dehydrogenase A (*Ldha*), uncoupling protein 2 (*Ucp2*), *Caspase 7*, and genes of fatty acid oxidation (Ma et al., 2007). Interestingly, previous reports in our laboratory have shown that diazoxide inhibited high glucose-induced expression of *Myc* and *Hmox1* (Jonas et al., 2001; Jonas et al., 2003). We also observed that high glucose-induced *Mt1a* expression was inhibited by diazoxide (MB and JCJ, unpublished

results). These observations suggest that β -cell rest interventions may also improve the β -cell phenotype by reducing oxidative stress.

Noteworthy, although diazoxide has been shown to reduce fatty acid-induced ER stress in INS1 cells, murine insulinoma cells (MIN6) cells and rat islets (Sargsyan et al., 2008), we observed that it did not affect high glucose-induced upregulation of ER stress markers in rat islets (Elouil et al., 2007). This finding suggests that glucose activation of the ER stress response is independent from excessive insulin secretion induced by prolonged exposure to high glucose.

Previous clinical trials with diazoxide in T2D patients who were treated with bedtime insulin moderately improved several parameters of β -cell function, but failed to improve metabolic control (Guldstrand et al., 2002; Qvigstad et al., 2004). In addition, co-treatment with insulin has been shown to be required to obtain the beneficial effects of diazoxide (Radtke et al., 2007). Therefore, despite the well demonstrated beneficial effects of diazoxide, the exploitation of these findings in the development of a therapeutic strategy in T2D patients requires further investigation.

3-2-2 Oxidative stress

ROS delineates a group of free radicals and molecules derived from molecular oxygen that play an important role in both physiology and pathology of several cell types including β -cells (Pi et al., 2010; Robertson, 2004). Under physiological conditions, they are generated continuously by mitochondria as a byproduct of oxidative phosphorylation (Turrens, 2003), but cells bring into play various antioxidant systems to rapidly neutralize ROS and maintain an optimal redox environment for proper biological function. However, this equilibrium is lost in diabetic individuals where enhanced ROS formation overwhelmed and/or decreased the antioxidant defenses of the organism. Oxidative stress leads to cellular damage which plays a central role in the development of diabetic complications, insulin resistance and β -cell dysfunction (Ceriello, 2003; Evans et al., 2002; Robertson, 2009; Son, 2007).

β -cells are vulnerable to oxidative stress due to their low expression of the principal antioxidant enzymes superoxide dismutase 1 and 2 (SOD1-2), glutathione peroxidase 1 (GPX1), and catalase (CAT) (Lenzen et al., 1996; Tiedge et al., 1997; Tonooka et al., 2007). In addition, it has been recently suggested that islets have poor DNA repair capacity against oxidative damage (Modak et al., 2009).

The link between oxidative stress and glucotoxicity has been suggested by earlier studies in β -cell lines, isolated islets, and diabetic animal models showing that antioxidants

can protect β -cells against the deleterious effects of high glucose levels on insulin secretion, insulin gene expression, islet insulin content and survival (Kaneto et al., 1996; Kaneto et al., 1999; Tajiri et al., 1997; Tajiri and Grill, 2000; Tanaka et al., 1999).

In agreement with these observations, it has been shown that high glucose increased ROS production in hamster insulinoma cells HIT-T15, MIN6 cells, rat islets, mouse islets as well as human islets (Bindokas et al., 2003; Morgan et al., 2007; Sakai et al., 2003; Tanaka et al., 2002; Zraika et al., 2006). Besides, it has been reported that islet cells of Zucker Diabetic Fatty (ZDF) rats and MKR mice presented a higher ROS content than their control littermates and showed in parallel, altered mitochondrial morphology and function (Bindokas et al., 2003; Lu et al., 2010). Although the mitochondrial respiratory chain is thought to be the major source of ROS, *in vitro* and *in vivo* observations support the involvement of NADPH oxidase (NOX) complexes also in this process (Morgan et al., 2007; Nakayama et al., 2005).

As shown in **table 1**, high glucose has also been shown to increase oxidative stress markers and to stimulate the expression of several oxidative stress-response genes in β -cell lines, isolated islets, the islets of diabetic animals, and the islets of human T2D subjects. Furthermore, overexpression of several antioxidant enzyme genes including *Cat*, *Gpx1*, *Hmox1*, *Mt*, *Sod1-2*, peroxiredoxin 3, and thioredoxin has been shown to protect β -cells against ROS toxicity (Chen et al., 2001; Hotta et al., 1998; Lortz et al., 2005; Lortz and Tiedge, 2003; Tanaka et al., 2002; Tobiasch et al., 2001; Wolf et al., 2010). Thus, compelling evidence indicates that β -cells suffer from oxidative stress under prolonged hyperglycemia.

But how do ROS alter the β -cell phenotype? Oxidative stress-mediated inhibition of insulin gene expression has been shown to stem in part from the well-established diminution of PDX-1 binding to the insulin promoter (Olson et al., 1993; Olson et al., 1995), as a result of reduced expression and nuclear exclusion by a mechanism involving the activation of c-jun N-terminal kinase (JNK) (Kaneto et al., 2002c; Kawamori et al., 2003). JNK activation has been shown to play a central role in β -cell apoptosis induced by culture in low glucose via a mechanism involving ROS inhibition of JNK-upstream phosphatases (Hou et al., 2008a), but it is unclear whether this mechanism is operative under high glucose. Moreover, high glucose-induced oxidative stress has been shown to contribute to the loss of insulin gene expression by reducing MafA protein levels in HIT-T15 cells (Harmon et al., 2005). High glucose can also suppress insulin gene transcription by upregulating the expression of *Myc* (Jonas et al., 2001; Kaneto et al., 2002a), an oxidative stress-activated gene that has been shown to play an important role in β -cell dysfunction and apoptosis (Elouil et al., 2005; Pascal et al., 2008; Pelengaris et al., 2002; Van de Casteele et al., 2003).

In addition, it has been previously demonstrated in rat and mouse β -cells that hydrogen peroxide (H_2O_2) induced the loss of mitochondrial membrane potential and reduced the intracellular ATP concentration, leading to the opening of K_{ATP} channels, hyperpolarization of plasma membrane and thereby, inhibition of GSIS (Krippeit-Drews et al., 1999; Maechler et al., 1999). Interestingly, the deleterious effects of H_2O_2 on β -cell function and survival were prevented by genetic or pharmacologic inhibition of K_{ATP} channel activity, at least in part, as a consequence of increased activity of the antioxidant enzymes SOD, GPX and CAT (Gier et al., 2009).

Moreover, ROS-mediated alteration of GSIS has been proposed to be related to the downregulation of GAPDH activity (Sakai et al., 2003). The latter may lead to the accumulation of upstream glycolytic metabolites which flow into several glucotoxic pathways, including the Advanced Glycation End products (AGEs) pathway (Brownlee, 2001). The inhibition of GAPDH activity may also hamper the glycolytic flow and NADH shuttling, which results in the inhibition of mitochondrial ATP generation and thereby, inhibition of GSIS (Eto et al., 1999).

It is well established that excessive ROS production induces important macromolecular damage. Of note, mitochondrial DNA is particularly susceptible to oxidative stress owing to the absence of histones, and the poor DNA-repair mechanisms (Yakes and Van, 1997). In addition, several mitochondrial proteins such as aconitase and adenine nucleotide translocase have been shown to be targets for oxidative damage (Yan et al., 1997; Yan and Sohal, 1998).

In view of the various evidences that oxidative stress is central to the pathogenesis of T2D, antioxidant therapy should be theoretically very beneficial to these patients. Antioxidant (pre)treatment of diabetic animal models (*Lepr^{db/db}* mice, ZDF rats, STZ-induced diabetic mice and rats etc.) provided some promising results over the last decade with regard to the protection against diabetic complications (Abiko et al., 2003; Fiordaliso et al., 2004; Pazdro and Burgess, 2010), the improvement of insulin sensitivity (Banday et al., 2005; Blouet et al., 2007; Houstis et al., 2006; Khamaisi et al., 1999; Song et al., 2005), and the enhancement of β -cell function and survival (Coskun et al., 2005; Dixit et al., 2010; Gorogawa et al., 2002; Harmon et al., 2009; Ihara et al., 2000; Kaneto et al., 1999; Kanter et al., 2004; Meghana et al., 2007; Sefi et al., 2011; Takatori et al., 2004; Tanaka et al., 1999).

Interestingly, clinical trials using seed extracts of *Silybum marianum* (Silymarin) alone or in combination with glibenclamide were very promising and showed a marked improvement of glycemic control in T2D patients (Huseini et al., 2006; Hussain, 2007). On

the other hand, the few pilot trials of antioxidant supplementation in humans yielded unpersuasive results and were in sum disappointing (Bashan et al., 2009; Evans, 2007; Pazdro and Burgess, 2010). Even more, some reports proposed that selenium and vitamin E supplementation may increase T2D risk and all-cause mortality respectively (Miller, III et al., 2005; Stranges et al., 2007).

However, it is possible that the antioxidants used targeted H_2O_2 which plays also an important signaling role, while the central player in β -cell oxidative stress may be the superoxide anion. Interestingly, it has been shown in our laboratory that H_2O_2 -induced alterations of rat islet function were prevented by addition of N-acetyl-L-cysteine (NAC) or the SOD mimetic agent, Mn(III)tetrakis(4-benzoic acid)porphyrin (chloride) (MnTBAP) to the culture medium. However, these antioxidants were unable to counter the functional alterations induced by prolonged exposure to high glucose (Khaldi et al., 2006). Alternatively, in the model of glucose infused rats, β -cell function was preserved *in vivo* and in isolated islets by co-infusion of the SOD mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (Tempol). The latter completely prevented islet total and mitochondrial superoxide generation while NAC and taurine failed (Tang et al., 2007).

3-2-3 ER stress

During the last decades, the ER stress pathway has emerged as an important mechanism implicated in the pathogenesis of several diseases including diabetes (Delepine et al., 2000; Ladiges et al., 2005; Laybutt et al., 2007b; Senee et al., 2004; Thameem et al., 2006) and its ensuing complications (Li et al., 2009; Lindenmeyer et al., 2008; Liu et al., 2008; Morse et al., 2010).

The ER is a cellular organelle that fulfills vital biological roles including lipid synthesis, protein synthesis, posttranslational modifications and correct folding. The latter is mandatory for proper function of proteins. Therefore, the ER is endowed with a set of ER-resident molecular chaperones and foldases, and contains a high Ca^{2+} concentration to allow their proper activity. However, an increase in ER client protein load or a decrease in chaperone function leads to the exhaustion of the ER folding capacity and accumulation of unfolded proteins. Face to this “stress”, a cellular adaptive response called the Unfolded Protein Response (UPR) is activated to restore ER homeostasis. The UPR is orchestrated by three master ER sensors: (i) the pancreatic ER kinase (PERK) which phosphorylates the α subunit of the translation initiation factor 2 (eIF2 α) on serine 51, leading to rapid and transient global reduction in protein translation to reduce ER-client protein load, with a paradoxical

increase in the translation of some rare transcripts, including activating transcription factor 4 (ATF4). The latter stimulates the expression of chaperones, antioxidant response genes, but also the proapoptotic effectors *Ddit3*, *Atf3*, and *Trb3*. Recently, it has been shown that eIF2 α phosphorylation also upregulates the expression of the apoptosis antagonizing transcription factor, a novel UPR effector that promotes β -cell survival under ER stress through transcriptional upregulation of v-akt murine thymoma viral oncogene homolog 1 (*Akt1*) (Ishigaki et al., 2010) (**Figure 3**); (ii) inositol requiring 1 (IRE1) which triggers the unconventional splicing of X-box binding protein 1 (*Xbp1*) pre-mRNA and subsequent increase in active XBP1. The latter, together with (iii) active ATF6, activates the expression of ER chaperone genes and ER-associated degradation (ERAD) genes in order to improve chaperone capacity, degrade the unfolded proteins and avoid ER proteotoxicity. Besides ERAD machinery, clearance of misfolded proteins may also occur through autophagy (Kaushik et al., 2010; Scheuner and Kaufman, 2008; Schroder, 2008; Schroder and Kaufman, 2005).

Importantly, since eIF2 α phosphorylation can be activated by other kinds of cellular stress independently from the UPR (Harding et al., 2003; Ma and Hendershot, 2004), increased mRNA levels of *Ddit3* and/or other ATF4-target genes alone should not be considered as signs of ER stress. It must be paralleled by PERK phosphorylation and/or the activation of IRE1 and/or ATF6. Therefore, we will designate the PERK arm of the UPR as the Integrated Stress Response (ISR) (Bensellam et al., 2009; Elouil et al., 2007; Ma and Hendershot, 2004).

If UPR activation fails to restore ER homeostasis under prolonged or intense ER stress, an apoptotic program is triggered, as depicted in **Figure 3**. This program involves the complex action of several not fully identified effectors including *Ddit3* (Oyadomari and Mori, 2004; Song et al., 2008), *Trb3* (Bromati et al., 2011; Liew et al., 2010), *Atf3* (Li et al., 2008), IRE1 (Han et al., 2009; Lipson et al., 2008; Pirot et al., 2007), and likely perturbations of Ca²⁺ homeostasis (Scorrano et al., 2003; Tsujimoto and Shimizu, 2007) (**Figure 3**).

β -cells are particularly sensitive to ER stress due to their high rate of proinsulin biosynthesis in response to glucose stimulation (see section 2-1). Therefore, adequate UPR response is vital for the maintenance of the functional β -cell mass, whereas exaggerated activation and/or genetic disruption of the UPR triggers β -cell apoptosis and induces diabetes in man and rodents (Oslowski and Urano, 2010; Scheuner and Kaufman, 2008).

The first evidence suggesting a role of UPR signaling in β -cell glucotoxicity comes from several reports showing increased expression/activation of UPR-ISR markers in β -cells

exposed to elevated glucose levels, either *in vitro* or *in vivo* (**Table 2**). However, despite the importance of these observations, upregulation of UPR makers alone do not prove a contributory role of ER stress in the glucotoxic alterations of the β -cell phenotype.

The second evidence linking UPR to β -cell glucotoxicity comes from genetic manipulations of UPR components and other genes in β -cell lines and mouse models. Thus, high glucose-induced downregulation of insulin gene expression in INS1 cells has been shown to be significantly prevented by *Atf6* silencing. In contrast, active ATF6 overexpression in INS1 cells inhibited insulin secretion and gene expression in parallel to a marked reduction in PDX-1 and MafA mRNA and protein levels (Seo et al., 2008). In the same model, it has been shown that *Trb3* overexpression inhibited GSIS, enhanced the deleterious effects of high glucose on cell growth, fostered high glucose-induced ROS production, and increased high glucose-induced apoptosis (Qian et al., 2008). Similarly, strong overexpression of *Xbp1* in rat islet cells reduced the degree of β -cell differentiation, inhibited GSIS, and increased β -cell apoptosis (Allagnat et al., 2010). On the other hand, *BiP* overexpression in INS1 cells partially prevented the toxic effects of chronic high glucose on insulin gene expression and proinsulin biosynthesis (Zhang et al., 2009).

In vivo, it has been shown that *Ddit3* deletion in *Lepr^{db/db}* mice prevented fasting hyperglycemia and glucose intolerance as a consequence of enhanced β -cell function, increased proliferation, and inhibition of apoptosis (Song et al., 2008). Recently, a study in glucose-infused rats has shown that co-infusion of the chemical chaperones 4-phenylbutyrate (PBA) or tauro-ursodeoxycholic acid (TUDCA) prevented hyperglycemia-induced β -cell dysfunction and markedly reduced the activation of several ER stress markers. Very interestingly, this study has also established a link between ER stress and oxidative stress pathways since the chemical chaperones reduced superoxide generation while Tempol prevented eIF2 α phosphorylation, *Ddit3* upregulation, and *Xbp1* splicing (Tang et al., 2012). These observations are in agreement with a previous study showing that prevention of eIF2 α phosphorylation in β -cells induced oxidative stress (Back et al., 2009). However, it is unclear which pathway operates upstream of the other. It is possible that increased mitochondrial superoxide generation leaks into the ER. Alternatively, protein folding and particularly disulfide-bond formation may also generate ROS.

Altogether, these observations suggest that excessive stimulation of the UPR pathway under prolonged or unresolved ER stress in parallel to the activation of the ISR branch plays an important role in β -cell glucotoxicity.

3-2-4 Protein glycation and AGE-receptors

Glucose and other reducing sugars can spontaneously react with amine residues on proteins, lipids, and nucleic acids to form stable covalent adducts known as AGEs (Huebschmann et al., 2006) (**Figure 4**). It is well established that hyperglycemia fosters this nonenzymatic glycation leading to intracellular AGEs accumulation and thereby, structural alterations of intracellular proteins (Brownlee, 2001). AGEs can also exert their toxic effects by diffusion out of the cell and modification of ECM proteins (Brownlee, 2001), and/or indirectly by binding to AGEs receptors (RAGE) and triggering various signalization cascades. Noteworthy, the activation of nuclear factor κ B (NF κ B) is a key target of RAGE signaling (Kim et al., 2005) (**Figure 4**).

Evidence suggested that high glucose levels increase protein glycation and AGEs formation in rat and mouse islets (Pascal et al., 2010; Tajiri et al., 1997). Interestingly, it has been previously reported that aminoguanidine (AG) (an inhibitor of AGEs formation) can preserve insulin gene expression, proinsulin biosynthesis and GSIS in HIT-T15 cells, INS1 cells and rat islets cultured in the presence of high glucose levels (Tajiri et al., 1997; Tajiri and Grill, 2000; Tanaka et al., 1999), and a similar beneficial effect was observed in the islets of ZDF rats (Tanaka et al., 1999). However, the effects of AG in the latter study were also mimicked by NAC, suggesting that AG may act by reducing high glucose-induced oxidative stress (Tanaka et al., 1999). Another possibility is that AGEs formation exerts its deleterious effects by triggering oxidative stress. Interestingly, AGEs treatment has been recently shown to increase β -cell ROS generation *in vitro* and *in vivo* in parallel to functional alterations. These effects were countered using antioxidants (Coughlan et al., 2011; Lin et al., 2012). It has also been shown that AGEs inhibited GSIS via nitric oxide-dependent inhibition of cytochrome c oxidase and ATP production in mouse islets and INS1 cells (Zhao et al., 2009) (**Figure 4**). In the latter model, AGEs treatment markedly reduced GSIS and increased apoptosis in a time and concentration-dependent manner in parallel to cytochrome c release from mitochondria, activation of effector caspases, and reduced insulin and *Bcl2* gene expression (Zhu et al., 2011) (**Figure 4**). These effects are thought to be mediated by the RAGEs since they were prevented by RAGE antibody or RAGE knockdown (Zhu et al., 2011). This concept was supported by the increased apoptosis rate observed in INS1 cells treated with RAGE ligands (Lee et al., 2010). AGEs have also been shown to decrease the expression and nuclear localization of PDX-1 together with increased levels of acetylated Forkhead box O1 (FoxO1) in HIT-T15 cells, giving thus a new insight on the mechanism by which AGEs can alter insulin gene expression (Puddu et al., 2010) (**Figure 4**).

On the other hand, studies on mice fed on a high AGE diet have shown that these animals become diabetic within 6 months and presented impaired pancreatic islet structure and function (Sandu et al., 2005). In agreement, *Lepr^{db/db}* mice fed on a low AGE diet showed improved insulin sensitivity and a better preserved structure of the islets (Hofmann et al., 2002).

Together, these results suggest that the AGEs pathway may play an important role in the loss of functional β -cell mass in diabetes, at least in part through the induction of oxidative stress and the alteration of β -cell differentiation and survival (**Figure 4**).

3-2-5 Hexosamine pathway

Evidence indicated that hyperglycemia can enhance glucose flux through a pathway that converts fructose-6-phosphate and glutamine into glucosamine-6-phosphate and glutamate by the rate-limiting enzyme of the pathway, glutamine:fructose-6-phosphate amidotransferase (GFAT). Then, glucosamine-6-phosphate is further metabolized to uridine diphosphate-N-acetylglucosamine which is the substrate of the O-linked β -N-acetylglucosamine transferase (OGT). This enzyme catalyzes the transfer of N-acetylglucosamine (*O*-GlcNacylation) on serine and/or threonine residues of target proteins including PDX-1 (Gao et al., 2003) and FoxO1 (Housley et al., 2008; Kuo et al., 2008). These enhanced *O*-GlcNac posttranslational modifications lead to protein gain/loss of function and subsequently, important changes in gene expression that have been proposed to contribute to β -cell glucotoxicity.

Thus, GFAT overexpression in isolated rat islets or glucosamine treatment impaired GSIS in parallel to increased H_2O_2 production, reduced DNA binding activity of PDX-1, and reduced expression of insulin, *Glut2* and *Gck*. These effects were reversed by NAC treatment (Kaneto et al., 2001). These results were confirmed and extended by another study showing that culture of rat islets in the presence of glucosamine inhibited GSIS and decreased the mRNA levels of *Glut2* and *Gck* while increasing those of hexokinase (*Hk*) (Yoshikawa et al., 2002). *In vivo*, the islets of diabetic Goto-Kakizaki (GK) rats exhibited increased expression and enzymatic activity of OGT alongside a global rise in islets protein *O*-GlcNacylation including PDX-1 (Akimoto et al., 2007). Besides, glucosamine infusion in rats markedly impaired GSIS (Shankar et al., 1998) and increased β -cell apoptosis (Liu et al., 2000). Finally, excessive activation of the hexosamine pathway has also been proposed to play a role in high glucose-induced human β -cells apoptosis (D'Alessandris et al., 2004).

However, if a growing body of data indicates that excessive *O*-GlcNac modification of proteins in β -cells may be deleterious, one should be aware that other evidence indicates that

the hexosamine pathway plays an important physiological role. Thus, either pharmacological inhibition of GFAT by azaserine or OGT knockdown in MIN6 cells reduced insulin secretion (Akimoto et al., 2007; Gao et al., 2003).

3-2-6 PKC activation

PKC is a family of serine/threonine kinases that play an important role in both β -cell physiology and pathology. It encompasses at least 10 isoforms classified into three subfamilies: classical PKCs (α , β I, β II and γ) regulated by Ca^{2+} and diacylglycerol (DAG), novel PKCs (δ , ϵ , θ and η) regulated by DAG, and atypical PKCs (ζ and ι/λ) regulated by neither Ca^{2+} nor DAG (Mellor and Parker, 1998).

Evidence from *in vitro* and *in vivo* experimentation has demonstrated that hyperglycemia preferentially activates PKC β II in several vascular tissues including retina, heart and aorta {Das Evcimen, 2007 DASEVCIMEN2007 /id}. Rat and mouse islets and β -cell lines express several isoforms of PKC including PKC β II (Carpenter et al., 2004; Kaneto et al., 2002b; Knutson and Hoenig, 1994). The activation of the latter has been shown to be partly involved in hyperglycemia-induced activation of *Myc* and subsequent reduction in insulin gene expression and GSIS (Kaneto et al., 2002a). In addition, PKC ϵ inhibition has been shown to improve GSIS in the islets of *Lepr^{db/db}* mice (Schmitz-Peiffer et al., 2007). In contrast, another report has shown that pharmacological activation of PKC ϵ decreased mouse islet cell apoptosis after isolation without affecting GSIS (Kvezereli et al., 2008).

Inhibition of PKC β has been shown to be a promising approach toward the treatment of microvascular complications in diabetic animals and humans (Clarke and Dodson, 2007; Ishii et al., 1996; Koya et al., 1997; Koya et al., 2000; Nonaka et al., 2000). However, until now and to our knowledge, no therapeutic approaches have been made toward the improvement of the functional β -cell mass in T2D subjects likely due to the multiplicity of PKC isoforms, their complex roles in β -cell pathophysiology, and the lack of specific inhibitors.

3-2-7 Inflammation

There is good evidence that inflammation is an important mechanism that contributes to the initiation, development, and progression of T2D (Donath and Shoelson, 2011; Kolb and Mandrup-Poulsen, 2005). The (pre)diabetic state is indeed characterized by a low-grade inflammation as evidenced by increased plasma levels of several inflammatory markers, including C-reactive protein (CRP), interleukine-1 β (IL-1 β), IL-6, tumor necrosis factor alpha

and white blood cell count (Donath and Shoelson, 2011; King, 2008). The proinflammatory cytokines and chemokines released by adipose tissue, endothelial cells, and immune cells under hyperglycemic conditions are thought to contribute to the inflammatory process in several tissues including the liver and pancreatic islets (Donath and Shoelson, 2011; King, 2008; Shoelson et al., 2006).

Thus, fibrosis, which generally results from inflammation, has been observed in the islets of ZDF rat (Pick et al., 1998), Otsuka Long Evans Tokushima Fatty (OLETF) rat (Ko et al., 2004), the Spontaneously Diabetic Torii rat (Masuyama et al., 2004), and GK rat (Homo-Delarche et al., 2006). In the latter model, islets fibrosis was accompanied by vascular alterations, overexpression of several genes involved in the inflammatory response, and increased macrophage and granulocyte staining around and inside the islets on pancreas sections (Homo-Delarche et al., 2006). These alterations have been proposed to stem from endothelial cell activation under hyperglycemic conditions, and subsequent increased expression of adhesion molecules and proinflammatory cytokines, including IL-1 β , which can affect β -cells directly and also by recruitment of immune cells (Lacraz et al., 2009b). Islet macrophage infiltration and increased expression of IL-1 β have also been reported in the pancreas sections of T2D patients (Ehse et al., 2007; Maedler et al., 2002).

Interestingly, IL-1 β expression and secretion have been shown to be upregulated in human islets cultured in the presence of high glucose levels. This was paralleled by increased NF κ B activation, reduced expression of endogenous IL-1 receptor antagonist (IL-1Ra), upregulation of the cell death receptor *Fas*, and increased β -cell death. These effects were opposed by addition of IL-1Ra to the culture medium, which prevented also high glucose induced inhibition of GSIS (Maedler et al., 2002). In agreement, a clinical trial using a recombinant human IL-1Ra in T2D patients showed improved glycemia, enhanced β -cell function, and reduced circulating levels of CRP and IL-6 even 39 weeks after IL-1Ra withdrawal (Larsen et al., 2007; Larsen et al., 2009).

However, high glucose-induced activation of NF κ B and subsequent stimulation of IL-1 β expression have neither been confirmed in our laboratory in isolated rat islets (Elouil et al., 2005), nor by others in purified human β -cells (Cnop et al., 2005), cultured human islets, and islets from T2D subjects (Welsh et al., 2005). Moreover, a recent report has demonstrated that mouse islets deficient in IL-1 receptors or *Fas* are not protected against high glucose or ribose-induced apoptosis (McKenzie et al., 2010). One plausible explanation of these conflicting results is the use of culture dishes coated with ECM in the former studies, which allows the proliferation of contaminating non-endocrine cells. Besides, the beneficial effect

observed after IL-1Ra treatment in T2D patients may be explained by a general effect on the whole body inflammation rather than a unique effect on β -cells.

Altogether, these observations highlight the intricate network of interactions between β -cells, immune cells, endothelial cells, and peripheral tissues in the hyperglycemic environment that contribute to the inflammatory process in T2D.

3-2-8 Islet amyloid deposition

The islets of T2D patients are characterized by the presence of amyloid deposits (Clark and Nilsson, 2004; Deng et al., 2004; Haataja et al., 2008). The latter are insoluble fibrils formed by the assembly of islet amyloid polypeptide (IAPP) soluble monomers (also known as amylin) into a linear rigid organization, which forms insoluble precipitates in the perivascular region and likely inside β -cells (Clark and Nilsson, 2004; Gurlo et al., 2010; Lin et al., 2007). IAPP is a 37-amino acid polypeptide of unclear physiological function, which is coexpressed and cosecreted with insulin by β -cells. IAPP has been shown to form amyloid in diabetic humans, monkeys, and cats but not in rodents due to proline substitutions in the hydrophobic amyloidogenic sequence (Clark and Nilsson, 2004).

Interestingly, amyloid deposits have also been observed in the islets of normoglycemic individuals. In addition, amyloid-containing islets presented only a slight decrease in proinsulin mRNA, refuting thereby a causative role of islet amyloidogenesis in the development of T2D (Sempoux et al., 2001). Nevertheless, *in vitro* and animal studies showed that it is small IAPP oligomers rather than amyloid fibrils that are toxic for β -cells. Thus, human IAPP (hIAPP) aggregates have been shown to induce β -cell death *in vitro* via a mechanism involving disruption of cell membrane (Janson et al., 1999). Besides, inhibition of IAPP expression in cultured human islets markedly reduced islet cell apoptosis, preserved islet architecture and enhanced β -cell function (Marzban et al., 2008). *In vivo*, it has been shown that IAPP oligomers are intracellular and do not colocalize with amyloid in transgenic mice overexpressing hIAPP in β -cells (Lin et al., 2007). These results are in agreement with previous observations that apoptotic β -cells in hIAPP-transgenic rodents were not adjacent to amyloid deposits (Butler et al., 2003; Butler et al., 2004). In hIAPP-transgenic mice, IAPP oligomers were present in the secretory pathway including ER, Golgi apparatus, and the secretory vesicles. Interestingly, electron microscopy revealed that IAPP aggregates were adjacent to disrupted ER, secretory vesicle and mitochondrial membrane in agreement with *in vitro* observations. Similarly, IAPP oligomers were also found in the secretory pathway of human T2D β -cells (Gurlo et al., 2010).

IAPP oligomerization may stem from the saturation and dysfunction of ER machinery under hyperglycemic conditions, which reduces its capacity to clear IAPP oligomers as they form. Thus, overexpression of hIAPP in rodent β -cells has been shown to induce ER stress (UPR and ISR) in parallel with the accumulation of polyubiquitylated proteins (Costes et al., 2011; Huang et al., 2007a). This accumulation has been shown to result from hIAPP-related deficiency in ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), an enzyme that allows access of proteins destined for degradation to the proteasome. Interestingly, UCH-L1 deficiency is also observed in human T2D islets (Costes et al., 2011). However, its dependence on IAPP aggregation in human T2D needs to be proven. Moreover, increased expression of hIAPP in rat β -cells has been shown to alter the autophagy pathway, which also plays an important role in the clearance of misfolded proteins (Rivera et al., 2011).

But until now, no report has demonstrated the colocalization of IAPP oligomers and apoptotic β -cells in T2D individual. Besides, the antibody used to detect these oligomers has been claimed to recognize other targets such as heat shock proteins (Zraika et al., 2010).

Overall, these observations suggest perhaps a role for amyloidogenesis in the alteration of the β -cell phenotype in T2D. The ER stress pathway may play a role in this process, particularly when the ER is overwhelmed under conditions of β -cell overstimulation.

3-2-9 Hypoxia

Hypoxia delineates a fall in tissue pO_2 below the normal level, which arises when O_2 demand exceeds O_2 supply. It leads to a metabolic crisis as manifested by reduced ATP production and increased mitochondrial ROS generation, and represents thereby a considerable threat to cell viability. Interestingly, hypoxic cells activate a master adaptive response orchestrated by the Hypoxia-Inducible Factor (HIF) family which enables cell survival through a switch from aerobic mitochondrial to anaerobic glycolytic ATP production, in parallel to the inactivation of pyruvate dehydrogenase and increased mitochondrial autophagy to prevent increased ROS generation (Semenza, 2010; Taylor, 2008).

HIFs are basic helix-loop-helix-PAS domain transcription factors composed of a regulated α subunit (either HIF1 α or HIF2 α), and a constitutively expressed HIF1 β subunit (Aryl-hydrocarbon-Receptor Nuclear Translocator (ARNT)). Under normoxic conditions, HIF α subunits are hydroxylated by prolyl-hydroxylase-domain proteins in an O_2 -, Fe^{2+} - and α -ketoglutarate-dependent manner. This hydroxylation promotes HIF α interaction with von Hippel-Lindau protein (VHL), leading to their polyubiquitylation and proteasomal degradation. Conversely, under hypoxic conditions, HIF α subunits are no longer degraded and

translocate with their dimerisation partner ARNT to the nucleus to activate the transcription of HIF-target genes including glycolytic enzymes, pyruvate dehydrogenase kinase 1 (*Pdk1*), the vasodilating peptide adrenomedullin (*Adm*), vascular endothelial growth factors, erythropoietin, etc (Benita et al., 2009; Elvidge et al., 2006; Semenza, 2010).

The HIF pathway plays an imperative role in the modulation of β -cell function, survival/proliferation, and glucose homeostasis. Thus, either excessive repression or excessive activation are deleterious for β -cells as revealed by the phenotypical alterations observed in mice lacking *vhl* (Cantley et al., 2009; Choi et al., 2011; Puri et al., 2009; Zehetner et al., 2008), *Arnt* (Gunton et al., 2005), and *Hif1 α* (Cheng et al., 2010), although the latter is controversial (Cantley et al., 2009). Besides, it has been previously reported that *Hif1 α* and *Arnt* expression were downregulated in islets isolated from the pancreases of dead T2D patients (Gunton et al., 2005), although these observations were not confirmed by others (Marselli et al., 2010).

In the context of glucotoxicity, islet perfusion experiments have shown increased basal and reduced maximal GSIS in *Vhl*-KO islets (Zehetner et al., 2008), an effect similar to that observed in rat islets cultured for 18h or one week in the presence of high glucose levels (Bensellam et al., 2009; Khaldi et al., 2004). Glucose stimulation is also known to increase respiration in INS1 cells (Spacek et al., 2008), and to increase islet O₂ consumption rate and reduce intra-islet pO₂ in rodents, primates, and humans (Gilbert et al., 2008; Jung et al., 2000; Jung et al., 2009; Longo et al., 1991; Sweet and Gilbert, 2006; Wang et al., 2005b). Moreover, islet blood flow regulation has been shown to be altered in diabetic animals (Carlsson et al., 1996; Svensson et al., 2000; Svensson et al., 2005), and high glucose has been shown to induce human islet endothelial cell apoptosis *in vitro* (Favaro et al., 2008). In agreement, several rodent models of T2D displayed marked alteration of islet vasculature, including *Lepi^{db/db}* mice (Shao et al., 2007), OLETF rats (Mizuno et al., 1999), GK rats (Homo-Delarche et al., 2006), and ZDF rats (Li et al., 2006). In the latter model, endothelium disruption was accompanied by increased islet expression of numerous HIF-target genes (Li et al., 2006).

Our microarray data revealed that most glycolytic enzymes and other HIF target genes, including *Adm* and *Pdk1*, were co-expressed and upregulated by glucose mostly between G10 and G30 (Bensellam et al., 2009), in agreement with previous observations in INS1 cells (Roche et al., 1997). Very interestingly, analysis of mouse islet proteome also revealed the upregulation of protein levels of several glycolytic enzymes after 24h culture in the presence of G16.7 instead of G5.6 (Waanders et al., 2009). We have recently demonstrated in INS1

cells and rat islets that these gene expression alterations stem from the acceleration of mitochondrial metabolism and O₂ consumption upon stimulation with high glucose concentrations, subsequent β -cell hypoxia, and nuclear expression of HIF1 and HIF2 (Bensellam et al., 2012). These findings are congruent with a recent study showing that high glucose induced HIF1 α activation in MIN6 cells, although only under mildly hypoxic conditions (10% O₂) (Sato et al., 2011). Interestingly, the glucose-dependent activation of HIF2 α and its requirement for the regulation of *Adm* expression in pancreatic β -cells has never been reported before, HIF2 α being usually considered absent from β -cells (Cantley et al., 2009; Heinis et al., 2010; Wiesener et al., 2003). Finally, we presented evidence suggesting that the high metabolic demand imposed by hyperglycemia in T2D may promote β -cell hypoxia *in vivo*. Thus, we observed increased mRNA levels of several HIF-target genes, including *Adm*, in the islets of *Lepr^{db/db}* mice, in good agreement with our *in vitro* data. We also detected rare HIF1 α -positive islet nuclei on pancreatic sections of *Lepr^{db/db}* mice but not normoglycemic *Lepr^{db/+}* mice, together with few islet cells exhibiting strong pimonidazole-protein adducts staining (a hypoxia marker) (Bensellam et al., 2012). In agreement, increased pimonidazole-protein adducts formation has been observed in isolated islets of other diabetic models (Sato et al., 2011).

These observations suggest that β -cells may suffer from hypoxia under conditions of hyperglycemia as a consequence of the acceleration of mitochondrial metabolism, increased ATP utilization, and limited O₂ supply, thereby leading to the alteration of islet gene expression (**Figure 5**). Since increased staining of HIF1 α and the proapoptotic HIF-target gene BCL2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) in hypoxic cultured or transplanted islets have been shown to correlate with increased β -cell apoptosis (Miao et al., 2006; Moritz et al., 2002), one could suggest that HIF activation and subsequent gene expression alterations in only a subpopulation of β -cells may contribute to the slow deterioration of β -cell function and survival in T2D.

3-2-10 Alteration of the β -cell differentiated phenotype

Differentiated cells, like β -cells, express characteristic transcription factors that coordinately activate or repress an array of genes, giving rise to a specific gene expression pattern. The latter allows these cells to have particular morphological and functional features. However, chronic hyperglycemia, through the activation of several glucotoxic pathways, down-regulates the expression of “ β -cell enriched genes” and the transcription factors that regulate their expression (**Table 3**).

Down-regulation of “ β -cell enriched genes” - The reduction of insulin gene expression is one of the earliest and most extensively studied glucotoxic alterations that has been characterized in β -cell lines and isolated rodent and human islets (Briaud et al., 1999; Marshak et al., 1999; Olson et al., 1998; Robertson et al., 1992). This reduction is observed after prolonged exposure to high glucose levels in β -cell lines, β -cells of diabetic animals, and β -cells of T2D patients. It has been shown to stem from decreased expression and binding of PDX-1 and MafA transcription factors to the insulin gene promoter (Gleason et al., 2000; Harmon et al., 1998; Marshak et al., 1999; Moran et al., 1997; Olson et al., 1995; Pino et al., 2005; Poitout et al., 1996; Sharma et al., 1995), increased expression of the transcriptional repressor CCAAT/enhancer-binding protein β (C/EBP β) (Lu et al., 1997; Seufert et al., 1998), and increased expression of *Myc* (Kaneto et al., 2002c). Interestingly, since the decrease of insulin gene expression is prevented by antioxidants, it may result from high glucose-induced oxidative stress (Robertson and Harmon, 2006; Tanaka et al., 1999), but other pathways could also be involved including ER stress (Han et al., 2009; Lipson et al., 2008; Pirot et al., 2007).

Besides, the islets of several animal models of T2D including 90% pancreatectomized (Px) rats, ZDF rats, *Lepr^{db/db}* mice, New Zealand Obese (NZO) mice and *Psammomys obesus* presented a marked decline in the expression of key islet transcription factors (Jonas et al., 1999; Kjørholt et al., 2005; Kluth et al., 2011; Leibowitz et al., 2001; Tokuyama et al., 1995). In parallel, these islets presented reduced expression of several GSIS key genes (Homo-Delarche et al., 2006; Jonas et al., 1999; Kjørholt et al., 2005; Laybutt et al., 2003; Thorens et al., 1992; Tokuyama et al., 1995; Zangen et al., 1997). A similar decrease in the expression of insulin, *Pdx-1*, *Glut2*, and *Gck* genes was observed in INS1 cells cultured for 48h in G30 (Wang et al., 2005a). On the other hand, studies in T2D patients confirmed some of these alterations, but not all (**Table 3**). Noteworthy, alterations in the expression of key metabolic genes resemble those observed in immature neonatal β -cells (Jermendy et al., 2011).

Interestingly, these alterations were normalized in the models of Px rats and *Lepr^{db/db}* mice by phlorizin but not bezafibrate, supporting their dependence on hyperglycemia rather than hyperlipidemia (Jonas et al., 1999; Kjørholt et al., 2005).

Moreover, high glucose levels have been shown to down-regulate the expression of several components of the β -cell exocytotic machinery including N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex proteins in INS1 cells (Dubois et al., 2007), several T2D animal models (Chan et al., 1999; Gaisano et al., 2002; Zhang et al., 2002), and in the islets of human T2D patients (Dubois et al., 2007; Ostenson et al., 2006). These alterations were also reversed by phlorizin treatment in GK rats (Gaisano et al., 2002),

and have been shown to involve the upregulation of several microRNAs (miRNAs) (Esguerra et al., 2011).

Up-regulation of “β-cell forbidden genes” - Concomitantly to the down-regulation of “β-cell enriched genes”, β-cells exposed to elevated glucose levels *in vitro* and *in vivo* exhibited an abnormal up-regulation of genes normally suppressed or expressed at very low levels (**Table 3**). They are characteristically induced by different kinds of stress and enclose both deleterious and protective genes that modulate in a complex manner the β-cell phenotype in response to hyperglycemia. They can be divided into three categories:

The first category encloses deleterious effectors. They include numerous transcription factors such as *Cebp/β* (Seufert et al., 1998), *Myc* (Jonas et al., 2001), *Crem* (Zhou et al., 2003), *Ddit3* (Song et al., 2008), *Atf3* (Hartman et al., 2004), and inhibitor of differentiation 1 (*Id1*) (Akerfeldt and Laybutt, 2011; Kjørholt et al., 2005), as well as several typical proapoptotic genes such as those of the *Bcl2* family (Federici et al., 2001; Laybutt et al., 2007b; Piro et al., 2002), *Fas* (Maedler et al., 2001), and thioredoxin-interacting protein (*Txnip*) (Chen et al., 2008; Minn et al., 2005; Shalev et al., 2002). Other deleterious genes include the inhibitor of AKT *Trb3* (Liew et al., 2010; Qian et al., 2008), the pro-oxydant enzyme *Nox1* (Marchetti et al., 2004), and the controversial proinflammatory cytokine IL1β (Elouil et al., 2005; Maedler et al., 2002).

The second category encloses effectors with protective effects against glucotoxicity. They comprise principally several antioxidant defense genes and components of the UPR (**Table 1 and 2**) (Bensellam et al., 2009; Elouil et al., 2005; Jonas et al., 2003; Jonas et al., 2009; Kjørholt et al., 2005; Lacraz et al., 2009a; Laybutt et al., 2002a; Marchetti et al., 2004; Marselli et al., 2010).

The third category encloses genes involved in metabolism including low- K_m *Hk1* and *Hk2* (Ghanaat-Pour et al., 2007; Jonas et al., 1999; Kjørholt et al., 2005; Laybutt et al., 2003), *Ldha* (Bensellam et al., 2009; Homo-Delarche et al., 2006; Jonas et al., 1999; Ma et al., 2007; Marselli et al., 2010), *Mct1*, *Mct2*, and *Mct4* (Bensellam et al., 2012; Laybutt et al., 2002b), glucose-6-phosphatase, fructose-1,6-bisphosphatase (Laybutt et al., 2002b), phosphoenolpyruvate carboxykinase 1 (Marselli et al., 2010; Shalev et al., 2002), and *Ucp2* (Anello et al., 2005; Kassis et al., 2000; Khaldi et al., 2004; Kjørholt et al., 2005; Laybutt et al., 2002b). Upregulation of these genes diverts glucose from its classical metabolism pathway, leading to the alteration of GSIS as evidenced in models of overexpression/deletion of some of these genes (Ainscow et al., 2000; Becker et al., 1994; Chan et al., 2001; Ishihara et al., 1994; Trinh et al., 1997; Zhang et al., 2001). Particularly, upregulation of *Hks*, and

likely other glycolytic genes, could explain the reduced glucose threshold for basal insulin secretion in *Psammomys obesus*, Px rats, and cultured rat islets (Bensellam et al., 2009; Hosokawa et al., 1995; Khaldi et al., 2004; Nesher et al., 1999). On the other hand, upregulation of *Ldha* and *Mcts* may hamper GSIS by diverting the flux of carbon from oxidative phosphorylation and ATP generation toward lactate production and transport, and may represent a sign of β -cell hypoxia (Bensellam et al., 2009; Bensellam et al., 2012; Jonas et al., 2009).

4- Future research directions

Understanding the molecular basis of β -cell pathophysiology is a fundamental step toward the development of efficient therapeutic strategies for T2D. The present review draws attention to the complexity of the problem and the multitude of biological pathways involved in β -cell glucotoxicity.

Actual treatments of T2D aim at the control of hyperglycemia through life style interventions (dietary management and development of physical activity) and antidiabetic drugs that increase insulin levels (insulin, sulfonylureas, incretin mimetics, dipeptidyl peptidase 4 (DPP-4) inhibitors), decrease insulin resistance (thiazolidinediones (TZDs), biguanides), and/or slow postprandial glucose absorption (glucosidase inhibitors, amylin) (reviewed in (Ahren, 2011; Chia and Egan, 2008; Drucker, 2006; Israili, 2011; Seino et al., 2012; Yki-Jarvinen, 2004)). Besides alleviating hyperglycemia, emerging experimental and clinical evidences indicate that some pharmacological therapies, but not all, have a direct beneficial effect on β -cells (reviewed in (Campbell and Mariz, 2007; Gupta et al., 2010; Marchetti et al., 2009; Wajchenberg, 2007)). As summarized in **table 4**, while the classical treatments such as metformin (biguanide), insulin and sulfonylureas are unable to avoid the progressive decline of β -cell function in already diabetic patients, the synthetic ligands of peroxisome proliferator-activated receptor γ TZDs, used primarily as insulin-sensitizers, as well as the incretin-mimetics and DPP-4 inhibitors have been shown to exert important beneficial effects on β -cell function and survival both *in vitro* and *in vivo*, at least in rodents. They are actually used in the treatment of T2D, mainly in combination with other drugs. However, the maintenance of their beneficial effect is not certain (**Table 4**). Besides, recent observations in humans suggest that they may represent a serious risk for the development of pancreatitis, several cancers and myocardial infarction (Elashoff et al., 2011; Friedland et al., 2012; Iyer et al., 2012; Nissen and Wolski, 2010). Other potentially interesting therapeutic

agents in clinical development include the sodium-glucose cotransporter type 2 (SGLT2) inhibitors that oppose glucotoxicity through the inhibition of renal glucose reabsorption (DeFronzo et al., 2012) (**Table 4**). Long-term studies are however required to evaluate their safety and the upholding (or not) of their beneficial effects.

Altogether, given the central role of β -cell dysfunction in the pathogenesis of T2D, the development of safer and more specific β -cell-directed therapies is mandatory, and understanding the molecular and cellular basis of β -cell glucotoxicity opens new therapeutical horizons in this direction. Very interestingly, experimental evidence support that the beneficial effect of some of the above mentioned drugs on β -cells may be related, at least in part, to an antioxidant effect (**Table 4**). Indeed, the oxidative stress pathway occupies a central place among the glucotoxic mechanisms since it exerts its deleterious effects not only through ROS production, but the latter can also activate other glucotoxic pathways. Alternatively, several glucotoxic pathways can stimulate ROS generation (Brownlee, 2001; Kaufman et al., 2010; Robertson, 2004). Therefore, despite the negative results of antioxidant supplementation in humans, catalytic antioxidants such as SOD mimetics and other mitochondria-targeted antioxidants may be more appropriate alone or in combination with the actually available anti-diabetic drugs and deserve further work (Bottino et al., 2004; Lim et al., 2011; Tang et al., 2007; Tang et al., 2012).

However, next generation T2D medicines aiming the preservation of functional β -cell mass should target more than one glucotoxic pathway. For example, catalytic antioxidants could be tested in combination with chemical and/or pharmacological chaperones to improve the UPR. Interestingly, the improvement of β -cell function and survival in *Lepr^{db/db}* mice after *Ddit3* deletion was paralleled by increased islet expression of several UPR and antioxidant response genes (Song et al., 2008). Besides, given the emerging role of AGEs in β -cell glucotoxicity, RAGE antibodies also deserve additional work and should be included in the therapeutic scheme (Zhu et al., 2011). Other glucotoxic pathways that may also be targeted include inflammation (Larsen et al., 2007; Larsen et al., 2009), and likely hypoxia (Bensellam et al., 2012). In addition, it has been reported that β -cell dysfunction and loss of differentiation in diabetes involves the upregulation of *Id1* (Akerfeldt and Laybutt, 2011; Kjørholt et al., 2005). Therefore, pharmacological inhibition of this transcriptional repressor could also be promising and merits further investigation.

Regarding the glucotoxic alterations of gene expression, one should be aware that the activity level of a given gene under a given condition at a given moment is not regulated only

by transcription and translation. In fact, the regulation of gene expression occurs also at other levels including mRNA stability (Tillmar et al., 2002), alternative mRNA splicing (Ortis et al., 2010), translational repression and/or mRNA degradation by miRNAs (Esguerra et al., 2011) and/or other mechanisms (Han et al., 2009), epigenetic regulation (Ng et al., 2010; Volkmar et al., 2012), and the modulation of protein levels (Waanders et al., 2009). Interestingly, the latter parameter is also subjected to an intricate regulation at several stages including translation (Greenman et al., 2007; Vander Mierde et al., 2007), post-translational modifications (including phosphorylation, hydroxylation, *O*-GlcNacylation etc.) (Akimoto et al., 2007; Kluth et al., 2011), stabilization/degradation (Bensellam et al., 2012), and enzymatic activity (Ling et al., 2001). Accordingly, large scale studies combining different technologies in the same models are required to gain more complete insights about the mechanisms of β -cell glucotoxicity.

5- Conclusion

Increasing evidence indicates that high glucose levels exert deleterious effects on the β -cell phenotype through the activation of numerous glucotoxic pathways both *in vitro* and *in vivo*. These findings are however just the tip of the iceberg. A deeper understanding of each pathway, its components and their mode of regulation, and how the switch occurs from physiological to glucotoxic role under chronic hyperglycemia, such as for the ER stress pathway and the hexosamine pathway, may reveal new paths toward the restoration of a functional β -cell mass in T2D.

Acknowledgments

M. Bensellam was Research Fellow of the Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Brussels, Belgium), and is actually supported by a Post-doctoral Fellowship from the Société Francophone du Diabète (SFD, Paris, France). J.C. Jonas is Research Director of the F.R.S.-FNRS. Our recent studies were supported by grants from the European Foundation for the Study of Diabetes, the SFD, the Fonds de la Recherche Scientifique Médicale (Brussels, Belgium) and the General Direction of Scientific Research of the French Community of Belgium.




Figure 1. Glucose exerts pleiotropic effects on the β cells depending on the intensity and the duration of stimulation. See the text for details. ER: Endoplasmic Reticulum; *Glut2*: Glucose transporter 2; *Pdx-1*: Pancreatic and duodenum homeobox-1.




Figure3. Schematic representation of the cascade of molecular events triggered by unresolved ER stress leading to cell death. Besides stimulating the expression of chaperones, ATF4 induces the expression of the proapoptotic effectors Ddit3, Atf3, and Trb3 which act through the repression of Bcl2 and Irs2 gene expression and AKT activity respectively. On the other hand, hyperactive IRE1 stimulates proapoptotic effectors including JNK, Ddit3 and Casp12, and degrades preproinsulin mRNA and likely other mRNAs leading to a decrease in the degree of β -cell differentiation. AATF: apoptosis antagonizing transcription factor; AKT: thymoma viral proto-oncogene 1; APAF1: Apoptotic peptidase-activating factor 1; ASK1: apoptosis signal-regulated kinase 1; ATFX: Activating transcription factor X; CaspX: Caspase X; BAK: BCL-2 homologous antagonist/killer; BAX: BCL-2-associated X protein; BCL-XL: BCL-x long; BCL2: B cell leukemia/lymphoma 2; BID: BH3 interacting domain death agonist; CYC: Cytochrome c; Ddit3: DNA damage inducible transcript 3; ER: Endoplasmic reticulum; JNK: c-Jun NH2-terminal kinase; IP3R: Inositol 1,4,5-trisphosphate receptor; IRE1: Inositol requiring 1; IRS2: Insulin receptor substrate 2; Mt: Mitochondria; PERK: double-stranded RNA activated protein kinase (PKR)-like ER kinase; RyR: Ryanodine receptor; TRAF2: Tumor necrosis factor receptor-associated factor 2; Trb3: Tribbles homologue 3.




Figure 4. Schematic representation of the molecular basis of the deleterious effects of AGEs on the β -cell phenotype. AGEs can either be formed inside β -cells or furnished by serum and adjacent cells such as endothelial cells. Mitochondrial ROS can stimulate AGEs formation by several mechanisms. One potential mechanism is the inhibition of GAPDH activity and subsequent accumulation of glyceraldehyde-3-phosphate (G3P), the precursor of methylglyoxal. Once formed, AGEs can stimulate ROS formation, thereby aggravating oxidative stress and leading to β -cell apoptosis. Recent evidence has shown that AGEs exert their deleterious effects predominantly by binding to their plasma membrane receptor RAGE and likely to other RAGE intracellular receptors. Activation of RAGE receptors triggers the expression of the acetylated form of FoxO1. The latter inhibits the expression and nuclear localization of PDX-1 leading to reduced insulin gene expression, which may explain in part the inhibitory effects of AGEs on GSIS and insulin content. In addition, AGEs-RAGE activates NFkB that stimulates the expression of inducible nitric oxide synthase (iNOS) and maybe other genes. Nitric oxide (NO) inhibits the cytochrome c oxidase (COX) leading to reduced ATP synthesis and GSIS. Moreover, RAGE activation inhibits the expression of the antiapoptotic gene Bcl2 and stimulates cytochrome c (Cyc) release into the cytosol, the activation of effector caspases (Casp) and β -cell apoptosis. ECM: Extracellular matrix; FN3K: fructosamine-3-kinase; FN3K-RP: FN3K related protein.




Figure 5. Schematic representation of the hypothetical role of high glucose-induced hypoxia and subsequent activation of the HIF pathway in β -cell pathophysiology. Glucose stimulation increases O_2 consumption in β -cells following the acceleration of mitochondrial metabolism and the activation of ATP consuming processes like protein synthesis, plasma membrane Ca^{2+} ATPase (PMCA) and SERCA pump activity and exocytosis. Besides, hyperglycemia has been shown to alter islet vasculature leading thereby to limited O_2 supply. Therefore, prolonged stimulation with high glucose concentrations leads to relative hypoxia. The latter trigger an adaptive response by activating HIF1 and/or 2. This response may favor β -cell survival at the price of altered glucose-stimulated insulin secretion (GSIS) through i) the reduction of mitochondrial respiration and ROS generation by upregulating the expression of Pdk1 and likely, stimulating mitochondrial autophagy, ii) increasing anaerobic glycolytic ATP generation via the upregulation of glycolytic enzymes, and iii) promoting angiogenesis and increasing islet blood flow at the islet level by upregulating the expression of Vegf and vasomodulating factors including adrenomedullin (Adm). Mitochondrial ROS generation, which has been shown to activate HIF in other cell types, may also participate to the activation of the HIF pathway in β -cells. Finally, if hypoxia is prolonged or associated with other stresses like oxidative stress and/or acidosis, this may lead to β -cell apoptosis.

Marker/Gene	<i>In vitro</i> model	<i>In vivo</i> model	Role	References
8-OHdG	INS1 cells, Rat islets	GK rat islets, OLETF rat islets, human T2D islets	Product of oxidative DNA damage	(Hou et al., 2008b; Ihara et al., 1999; Nakayama et al., 2005; Sakuraba et al., 2002)
HNE-modified proteins		GK rat islets, <i>Lepr^{db/db}</i> mouse islets	Marker of lipid peroxidation	(Gorogawa et al., 2002; Ihara et al., 1999)
<i>Cat</i>		GK rat islets	Anti-oxidant	(Lacraz et al., 2009a)
<i>Cox2</i>		GK rat islets	Pro-oxidant	(Lacraz et al., 2010)
<i>Gpx1</i>		Px rat islets, <i>Lepr^{db/db}</i> mouse islets, GK rat islets, human T2D islets	Anti-oxidant	(Kjorholt et al., 2005; Lacraz et al., 2009a; Laybutt et al., 2002a; Marchetti et al., 2004)
<i>Gpx2</i>	Rat islets		Anti-oxidant	(Bensellam et al., 2009)
<i>G6pd*</i>	Rat islets	GK rat islets	Glucose metabolism, Anti-oxidant	(Bensellam et al., 2009; Lacraz et al., 2009a)
<i>Hmox1</i>	Rat islets	Px rat islets, <i>Lepr^{db/db}</i> mouse islets, GK rat islets	Anti-oxidant	(Elouil et al., 2005; Jonas et al., 2003; Kjorholt et al., 2005; Lacraz et al., 2009a; Laybutt et al., 2002a)
<i>Mt1a</i>	Rat islets		Anti-oxidant	(Bensellam et al., 2009)
<i>Mt1e</i> , <i>Mt1g</i> , <i>Mt1m</i> , <i>Mt1x</i>		Human T2D islets	Anti-oxidant	(Marselli et al., 2010)
<i>Mt2a</i>	Rat islets	Human T2D islets	Anti-oxidant	(Bensellam et al., 2009; Marselli et al., 2010)
<i>Myc</i>	Rat islets	Px rat islets, GK rat islets	Pro-apoptotic	(Elouil et al., 2005; Jonas et al., 2001; Lacraz et al., 2010)
<i>Nox1</i>		Human T2D islets	Pro-oxidant	(Marchetti et al., 2004)
<i>Nox2</i>		GK rat islets	Pro-oxidant	(Lacraz et al., 2010)
<i>Nrf2/Nfe2l2</i>		GK rat islets	Anti-oxidant	(Lacraz et al., 2009a)
<i>Prxd1</i>		GK rat islets	Anti-oxidant	(Lacraz et al., 2009a)
<i>Prxd2</i>		GK rat islets	Anti-oxidant	(Lacraz et al., 2009a)

<i>Sod1</i>		Px rat islets, GK rat islets	Anti-oxidant	(Lacraz et al., 2009a; Laybutt et al., 2002a)
<i>Sod2</i>	Rat islets	Px rat islets, GK rat islets, human T2D islets	Anti-oxidant	(Bensellam et al., 2009; Lacraz et al., 2009a; Laybutt et al., 2002a; Marselli et al., 2010)
<i>Srxn1</i>	Rat islets		Anti-oxidant	(Bensellam et al., 2009)
<i>Txnip</i>	INS1 cells, rat islets, Human islets	GK rat islets	Pro-apoptotic	(Bensellam et al., 2009; Homo-Delarche et al., 2006; Shalev et al., 2002; Shao et al., 2010)
<i>Txn1</i>		GK rat islets	Anti-oxidant	(Lacraz et al., 2009a)
<i>Txn2</i>		GK rat islets	Anti-oxidant	(Lacraz et al., 2009a)
<i>Ucp2</i>	Rat islets	Glucose-infused rat islets, Px rat islets, <i>Lepr^{db/db}</i> mouse islets, <i>Lep^{ob/ob}</i> mouse islets, ZDF rat islets	Anti-oxidant, impair GSIS	(Kassis et al., 2000; Khaldi et al., 2004; Kjørholt et al., 2005; Laybutt et al., 2002a; Oberkofler et al., 2009; Zhang et al., 2001)

Table 1. Selection of oxidative stress markers and antioxidant response genes upregulated by high glucose levels in in vitro and in vivo models. 8-OHdG: 8-hydroxydeoxyguanosine; Cat: Catalase; Cox2: Cyclooxygenase 2; Gpx: Glutathione peroxidase; G6pd: glucose-6-phosphate dehydrogenase; Hmox1: Heme oxygenase 1; HNE: 4-hydroxy-2-nonenal; Mt: Metallothionein; Myc: myelocytomatosis viral oncogene homolog (avian); Nox: NADPH oxidase; Nrf2: NF-E2-related factor 2; Prxd: Peroxiredoxin; Sod: Superoxide dismutase; Srxn1: Sulfiredoxin1; Txnip: Thioredoxin-interacting protein; Txn: Thioredoxin; Ucp2: Uncoupling protein 2.* Our results contrast with another study showing that the expression and activity of G6pd is downregulated in mouse and human islets cultured in the presence of elevated glucose concentrations (Zhang et al., 2010).

UPR

Marker/Gene	Model	Reference
IRE hyperactivation	INS1 cells	(Lipson et al., 2006; Lipson et al., 2008)
	Mouse islets	(Lipson et al., 2006; Lipson et al., 2008)
<i>Xbp1</i> mRNA splicing	INS1 cells	(Seo et al., 2008)
	Rat islets	(Bensellam et al., 2009; Elouil et al., 2007)
Activated ATF6	Mouse islets	(Jonas et al., 2009)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	INS1 cells	(Seo et al., 2008)
<i>BiP</i> (chaperone)	OLETF rat islets	(Seo et al., 2008)
	INS1 cells	(Wang et al., 2005a)
	Rat islets	(Elouil et al., 2007)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	MKR mouse islets	(Lu et al., 2008)
<i>Dnajc3</i> (chaperone)	Human T2D islets	(Laybutt et al., 2007b)
	Rat islets	(Bensellam et al., 2009)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	MKR mouse islets	(Lu et al., 2008)
	Human T2D islets	(Laybutt et al., 2007b)
<i>Fkbp11</i> (foldase)	Rat islets	(Bensellam et al., 2009)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	MKR mouse islets	(Lu et al., 2008)
<i>Edem1</i> (ERAD)	Rat islets	(Bensellam et al., 2009; Elouil et al., 2007)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)

ISR

Marker/Gene	Model	Reference
PERK phosphorylation	INS1 cells	(Hou et al., 2008b)
	eIF2 α phosphorylation	(Hou et al., 2008b; Seo et al., 2008)
<i>Atf4</i>	OLETF rat islets	(Seo et al., 2008)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	INS1 cells	(Hou et al., 2008b)
	Rat islets	(Hou et al., 2008b)
<i>Atf3</i>	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	Rat islets	(Elouil et al., 2007)
	<i>Lepr^{db/db}</i> mouse islets	(Kjorholt et al., 2005)
	Human T2D islets	(Hartman et al., 2004)
<i>Ddit3</i>	INS1 cells	(Hou et al., 2008b; Seo et al., 2008; Wang et al., 2005a)
	Rat islets	(Elouil et al., 2007; Hou et al., 2008b)
	<i>Lepr^{db/db}</i> mouse islets	(Laybutt et al., 2007b)
	Human T2D islets	(Huang et al., 2007a; Laybutt et al., 2007b)
<i>Trb3</i>	INS1-r β cells	(Qian et al., 2008)
	GK rat islets	(Qian et al., 2008)
	<i>Lep^{ob/ob}</i> mouse islets	(Liew et al., 2010)
	Human T2D islets	(Liew et al., 2010)

Table 2. Activation/upregulation of selected UPR-ISR markers in β -cells exposed to elevated glucose levels in vitro and/or in vivo. Atf: Activating transcription factor; BiP: Binding Ig Protein; Ddit3: DNA damage inducible transcript 3; Dnajc3: DNAJ (Hsp40) homologue C3; Edem1: ER degradation enhancer, mannosidase α -like 1; eIF2 α : eukaryotic translation initiation factor 2 α ; Fkbp11: FK506 binding protein 11; IRE: Inositol requiring 1; PERK: double-stranded RNA activated protein kinase (PKR)-like ER kinase; Trb3: Tribbles homologue 3; Xbp1: X-box binding protein 1.

Genes	Glucotoxicity model	Effect of hyperglycemia	References
β-cell enriched genes			
Islet hormones			
<i>Proinsulin</i>	HIT-T15 cells	Down	(Robertson et al., 1992; Sharma et al., 1995)
	β -TC6 cells	Down	(Poitout et al., 1996)
	INS1 cells	Down	(Olson et al., 1998)
	Rat islets	Down	(Briaud et al., 1999)
	Px rat islets	Down	(Zangen et al., 1997)
	ZDF rat islets	Down	(Tokuyama et al., 1995)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)
	<i>Psammomys obesus</i>	Down	(Leibowitz et al., 2001)
	Human islets	Down	(Marshak et al., 1999)
	Human T2D islets	Down	(DelGuerra et al., 2005; Marchetti et al., 2004)
<i>Iapp</i>	Px rat islets	Down	(Laybutt et al., 2003)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)
	Human T2D islets	Down	(Marselli et al., 2010)
Transcription factors			
<i>Pdx-1</i>	INS1 cells	Down	(Hou et al., 2008b; Wang et al., 2005a)
	Rat islets	Down	(Hou et al., 2008b)
	Px rat islets	Down	(Jonas et al., 1999; Zangen et al., 1997)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)
	NZO mouse islets	Down (protein)	(Kluth et al., 2011)
	Human T2D islets	Controversial: Slightly down, unchanged, up	(DelGuerra et al., 2005; Gunton et al., 2005; Marselli et al., 2010; Ostenson et al., 2006)
<i>MafA</i>	HIT-T15 cells	Down	(Sharma et al., 1995)
	NZO mouse islets	Down (protein)	(Kluth et al., 2011)
<i>NeuroD1</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)

<i>Nkx6.1</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	NZO mouse islets	Down (protein)	(Kluth et al., 2011)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)
<i>Hnf1α/Tcf1</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	Human T2D islets	Down	(Marselli et al., 2010)
<i>Hnf4α</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	Human T2D islets	Down	(Gunton et al., 2005)
Glucose metabolism			
<i>Glut2</i>	INS1 cells	Down	(Wang et al., 2005a)
	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	<i>Lepr^{db/db}</i> mouse islets	Down	(Kjorholt et al., 2005)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)
	Human T2D islets	Down	(Marselli et al., 2010)
<i>Gck</i>	INS1 cells	Down	(Wang et al., 2005a)
	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	ZDF rat islets	Down	(Tokuyama et al., 1995)
	Rat islets transplanted into diabetic rats	Down	(Laybutt et al., 2007a)
<i>Pc</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	<i>Lepr^{db/db}</i> mouse islets	Down	(Kjorholt et al., 2005)
	MKR mouse islets	Down	(Lu et al., 2008)
<i>mGpdh/Gpd2</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	ZDF rat islets	Down	(Tokuyama et al., 1995)
	MKR mouse islets	Down	(Lu et al., 2008)
	Human T2D islets	Down	(MacDonald et al., 2009; Marselli et al., 2010)
<i>Acly</i>	GK rat islets	Down	(Homo-Delarche et al., 2006)
	Human T2D islets	Down	(MacDonald et al., 2009; Marselli et al., 2010)
Ion channels and pumps			
<i>Kcnj11</i>	Px rat islets	Down	(Jonas et al., 1999; Laybutt et al., 2003)
	ZDF rat islets	Down	(Tokuyama et al., 1995)

	<i>Lepr^{db/db}</i> mouse islets	Down	(Kjorholt et al., 2005)
<i>Abcc8</i>	Human T2D islets	Down	(Marselli et al., 2010)
<i>Vdcca1D</i>	Px rat islets	Down	(Jonas et al., 1999)
	ZDF rat islets	Down	(Tokuyama et al., 1995)
	Human T2D islets	Down	(Marselli et al., 2010)
<i>Vdccb</i>	Px rat islets	Down	(Laybutt et al., 2003)
<i>Serca2b</i>	Px rat islets	Down	(Jonas et al., 1999)
	<i>Lepr^{db/db}</i> mouse islets	Down	(Kjorholt et al., 2005)
<i>Serca3</i>	Px rat islets	Down	(Jonas et al., 1999)
	<i>Lepr^{db/db}</i> mouse islets	Down	(Kjorholt et al., 2005)
β-cell forbidden genes			
Transcription factors			
<i>C/EBPβ</i>	HIT-T15 cells	Up	(Lu et al., 1997)
	INS1 cells	Up	(Lu et al., 1997)
	Px rat islets	Up	(Seufert et al., 1998)
	ZDF rat islets	Up	(Seufert et al., 1998)
<i>Crem</i>	Rat islets	Up	(Bensellam et al., 2009; Zhou et al., 2003)
<i>Id1</i>	<i>Lepr^{db/db}</i> mouse islets	Up	(Kjorholt et al., 2005)
	Human islets	Up	(Wice et al., 2001)
	Human T2D islets	Up (protein)	DR. Laybutt (unpublished results)
<i>Myc</i>	Rat islets	Up	(Bensellam et al., 2009; Elouil et al., 2005; Kaneto et al., 2002a)
	Px rat islets	Up	(Jonas et al., 1999; Jonas et al., 2001)
	GK rat islets	Up	(Lacraz et al., 2010)
Glucose metabolism			
<i>Hk1</i>	Px rat islets	Up	(Jonas et al., 1999)
	ZDF rat islets	Up (enzymatic activity)	(Cockburn et al., 1997)
	<i>Lepr^{db/db}</i> mouse islets	Up	(Kjorholt et al., 2005)
	<i>Psammomys obesus</i>	Up (enzymatic activity)	(Nesher et al., 1999)
<i>Hk2</i>	Rat islets	Up	(Ghanaat-Pour et al., 2007)
<i>G6pase</i>	Px rat islets	Up	(Laybutt et al., 2002b)
	GK rat islets	Up (enzymatic activity)	(Ling et al., 2001)

<i>Fbp1</i>	Px rat islets	Up	(Laybutt et al., 2002b)
<i>Pck1</i>	Human islets	Up	(Shalev et al., 2002)
	Human T2D islets	Up	(Marselli et al., 2010)
<i>Ldha</i>	Rat islets		(Bensellam et al., 2009; Bensellam et al., 2012; Ma et al., 2007)
	Px rat islets	Up	(Jonas et al., 1999; Laybutt et al., 2003)
	GK rat islets	Up	(Homo-Delarche et al., 2006)
	Rat islets transplanted into diabetic rats	Up	(Laybutt et al., 2007a)
	Human T2D islets	Up	(Marselli et al., 2010)
<i>Mct1</i>	Px rat islets	Up	(Laybutt et al., 2002b)
<i>Mct2</i>	Px rat islets	Up	(Laybutt et al., 2002b)
<i>Mct4</i>	Rat islets	Up	(Bensellam et al., 2012)
	Px rat islets	Up	(Laybutt et al., 2002b)
<i>Ucp2</i>	Rat islets	Up	(Khaldi et al., 2004)
	Glucose-infused rat islets	Up	(Kassis et al., 2000)
	Px rat islets	Up	(Laybutt et al., 2002b)
	ZDF rat islets	Up	(Oberkofler et al., 2009)
	<i>Lep^{ob/ob}</i> mouse islets	Up	(Zhang et al., 2001)
	<i>Lepr^{db/db}</i> mouse islets	Up	(Kjorholt et al., 2005)
	Human islets	Up (protein only)	(Li et al., 2008)
	Human T2D islets	Up (protein only)	(Anello et al., 2005)

Table 3. Alteration of the β -cell differentiated phenotype. The table represents a selection of important “ β -cell enriched genes” and “ β -cell forbidden genes” that have been shown to be down-regulated and up-regulated respectively by high glucose levels in several in vitro and in vivo models of β -cell glucotoxicity as well as in human T2D islets for some of them. *Abcc8*: ATP-binding cassette transporter sub-family C member 8; *Acy*: ATP citrate lyase; *C/EBP β* : CCAAT/enhancer-binding protein β ; *Crem*: cAMP Response-Element Modulator; *Fbp1*: fructose-1,6-bisphosphatase; *G6pase*: glucose-6-phosphatase; *Gck*: Glucokinase; *Glut2*: Glucose transporter 2; *Hnf*: Hepatocyte nuclear factor; *Hk*: Hexokinase; *Iapp*: Islet amyloid polypeptide; *Id1*: Inhibitor of differentiation 1; *Kcnj11*: Potassium inwardly rectifying channel, subfamily J, member 11; *Ldha*: Lactate dehydrogenase A; *MafA*: V-maf musculoaponeurotic fibrosarcoma oncogene homologue A; *Mct*: Monocarboxylate transporter; *mGpdh*: mitochondrial glycerol-3-phosphate dehydrogenase; *Myc*: myelocytomatosis viral oncogene homolog (avian); *NeuroD1*: neurogenic differentiation 1; *Nkx6.1*: NK6 transcription factor related, locus 1; *Pc*: Pyruvate carboxylase; *Pck1*: phosphoenolpyruvate

carboxykinase 1; Pdx-1: Pancreatic and duodenum homeobox-1; Serca: sarcoendoplasmic reticulum Ca^{2+} -ATPase; Ucp2: Uncoupling protein 2; Vdca: Voltage-dependent Ca^{2+} channel.

Treatment	Effects on β -cell	Development phase	Outcome
Early intensive insulin therapy / Insulin	- Prevention of β-cell loss in an animal model of diabetes (Kautz et al., 2012) - Improvement of β-cell function in T2D patients, likely by opposing glucotoxicity (Glaser et al., 1988; Gormley et al., 1986; Harrison et al., 2012; Li et al., 2004; Ryan et al., 2004; Yki-Jarvinen et al., 1988)	Clinical use / clinical trials	- Debated long-term beneficial effect (Gormley et al., 1986; Harrison et al., 2012; Li et al., 2004; Ryan et al., 2004; Yki-Jarvinen et al., 1988) - Progressive loss of β-cell function despite intensive therapy (Turner, 1998; UKPDS, 1998)
Sulfonylureas	- Closure of the K_{ATP} channel and stimulation of insulin secretion (Aguilar-Bryan and Bryan, 1999) - Controversial effect on insulin granule exocytosis <i>in vitro</i> (Eliasson et al., 1996; Garcia-Barrado et al., 1996; Mariot et al., 1998; Tian et al., 1998) - Potential antioxidant/antiapoptotic effect <i>in vitro</i> and <i>in vivo</i> through ROS scavenging and increased activity of antioxidant enzymes (DelGuerra et al., 2007; Gier et al., 2009; Jennings and Belch, 2000; Kimoto et al., 2003; O'Brien et al., 2000) - Controversial proapoptotic effect <i>in vitro</i> (Efanova et al., 1998; Maedler et al., 2005)	Clinical use	- Progressive loss of β-cell function despite intensive therapy (Harrower, 1994; Turner, 1998; UKPDS, 1998)
Metformin	- Indirect effect via insulin sensitization (Setter et al., 2003) - Protection of β-cells against glucotoxicity and restoration of GSIS in human T2D islets <i>in vitro</i> likely via an antioxidant/antiapoptotic effect (Lupi et al., 1999; Marchetti et al., 2004; Patane et al., 2000) - Delay of T2D incidence in high risk	Clinical use	- Progressive loss of β-cell function despite intensive therapy (Turner, 1998; UKPDS, 1998)

	individuals through enhancement of insulin sensitivity and β -cell function (Kitabchi et al., 2005; Knowler et al., 2002)		
Diazoxide and other K_{ATP} channel openers	- Opening of the K_{ATP} channel and inhibition of insulin secretion and thereby induction of β-cell “rest” - Restoration of β-cell function altered by high glucose levels <i>in vitro</i> (Bjorklund and Grill, 1993; Ritzel et al., 2004; Song et al., 2003; Yoshikawa et al., 2004) and in animal models (Bjorklund et al., 2004; Huang et al., 2007b) in association with complex transcriptional changes (Ma et al., 2007) - Potential antiapoptotic effect <i>in vitro</i> and in a T2D animal model (Efanova et al., 1998; Huang et al., 2007b) - Moderate effect on β-cell function in T2D patients (Guldstrand et al., 2002; Qvigstad et al., 2004; Radtke et al., 2007)	Clinical trials	Despite interesting experimental evidences, the impact on β -cell function in T2D patients is very moderate and it does not improve the metabolic control
TZDs	- Indirect effect via insulin sensitization (Yki-Jarvinen, 2004) - Protection of β-cells against high glucose induced apoptosis and loss of GSIS <i>in vitro</i> (Zeender et al., 2004) - Protection of β-cells against oxidative stress <i>in vitro</i> likely through upregulation of catalase gene expression (Chung et al., 2011) - Preservation of islet structure and improvement of pancreatic insulin content and β-cell function and survival in animal models of T2D (Diani et al., 2004; Finegood et al., 2001; Yajima et al., 2003)	Clinical use / clinical trials	- Improvement of β -cell function in T2D patients and IGT subjects despite some controversies (Hung et al., 2005; Seufert and Urquhart, 2008)

	- Prevention/delay of T2D in animals and high risk individuals in parallel to the enhancement of β-cell function (Gerstein et al., 2006; Higa et al., 1999; Knowler et al., 2005; Smith et al., 2000; Xiang et al., 2006) - Improvement of the glycemic control in (pre)diabetic subjects in parallel to the improvement of β-cell function (Cavaghan et al., 1997; Miyazaki et al., 2002; Miyazaki and DeFronzo, 2008; Ovalle and Bell, 2004; Smith et al., 2004; Wallace et al., 2004)		
Incretin-related medicines (GLP-1 analogues and DPP-4 inhibitors)	- Glucose-dependent stimulation of insulin secretion (Drucker, 2006) - Stimulation of the expression of β-cell enriched genes in the islets of T2D subjects <i>in vitro</i> (Lupi et al., 2008) - Inhibition of β-cell apoptosis induced by high glucose levels <i>in vitro</i> (Buteau et al., 2004) and in animal models of T2D (Farilla et al., 2002) likely through the activation of PKB (Buteau et al., 2004) and/or an antioxidant effect (Li et al., 2003; Liu et al., 2012; Pospisilik et al., 2003) - Potential restoration of β-cell function in the islets of T2D individuals <i>in vitro</i> (Lupi et al., 2008) - Stimulation of β-cell proliferation and neogenesis and restoration of β-cell mass in animal models of T2D (Farilla et al., 2002; Mu et al., 2006; Mu et al., 2009; Perfetti et al., 2000; Xu et al., 1999) - Improvement of glycemic control and β-cell	Clinical use / clinical trials /	- Improvement of β-cell function in T2D patients and IGT subjects - Uncertain effect on β-cell mass in humans - Uncertain long-term beneficial effect

	function in diabetic animals and T2D patients (Bunck et al., 2009; Greig et al., 1999; Mu et al., 2006; Mu et al., 2009; Scherbaum et al., 2008; Young et al., 1999)		
IL-1Ra (Anakinra)	- Prevention of high glucose-induced inhibition of GSIS and β-cell apoptosis <i>in vitro</i> likely through the inhibition of NFκB, Fas and IL-1β expression (Maedler et al., 2002) - Improvement of glycemic control and β-cell function in parallel to the reduction of islet inflammation in an animal model of T2D (Ehse et al., 2009) - Improvement of glycemic control and β-cell function in T2D patients in parallel to the reduction of markers of systemic inflammation (Larsen et al., 2007)	Experimental / clinical trials	- Improvement of glycemic control and β-cell function in T2D patients - Long-term beneficial effect only in a subpopulation of T2D individuals (Larsen et al., 2009) - Since high glucose-induced activation of NFκB and subsequent upregulation of IL-1β in β-cells is controversial (Cnop et al., 2005; Elouil et al., 2005; Welsh et al., 2005), the effect of IL-1Ra may be on whole body inflammation and not specifically on β-cells in T2D patients
Glucokinase activators	- Indirect effect via the modulation of hepatocyte glucose metabolism (Eiki et al., 2011; Fyfe et al., 2007) - Stimulation of the expression of β-cell enriched genes <i>in vitro</i> (Gill et al., 2011) - Stimulation of β-cell proliferation <i>in vitro</i> in association with increased expression of <i>Irs2</i> (Nakamura et al., 2009; Wei et al., 2009) - Stimulation of β-cell hypertrophy <i>in vitro</i> (McGlasson et al., 2011) - Enhancement of GSIS <i>in vitro</i> (Eiki et al., 2011; Fyfe et al., 2007; Gill et al., 2011; Johnson et al., 2007) - Prevention of high glucose-induced β-cell apoptosis <i>in vitro</i> (Wei et al., 2009) and	Experimental / clinical trials	- Improvement of glycemic control and β-cell function in T2D patients - Likely a promising therapy - Uncertain long-term beneficial effect (Meininger et al., 2011)

	preservation of β-cell mass in an animal model of T2D (Futamura et al., 2012) - Prevention of H_2O_2 induced alterations of β-cell function and survival <i>in vitro</i> (Futamura et al., 2012) - Delay of the onset of diabetes in an animal model of T2D (Futamura et al., 2012) - Improvement of glycemic control in animal models of T2D (Eiki et al., 2011; Fyfe et al., 2007; Nakamura et al., 2009) - Improvement of glycemic control and β-cell function in T2D patients (Bonadonna et al., 2010)		
SGLT2 inhibitors	- Indirect effect via the inhibition of renal glucose reabsorption (DeFronzo et al., 2012) - Improvement of glycemic control and functional β-cell mass in animal models of T2D, likely by opposing glucotoxicity (Fujimori et al., 2008; Fujimori et al., 2009; Jurczak et al., 2011; Katsuno et al., 2009; Suzuki et al., 2012; Yamamoto et al., 2011) - Improvement of glycemic control in T2D patients (Bailey et al., 2010; Ferrannini et al., 2010; Komoroski et al., 2009; Wilding et al., 2009; Zambrowicz et al., 2012)	Experimental / clinical trials	- Improvement of glycemic control in T2D patients - Potential negative effect on energy homeostasis in T2D patients -Uncertain long-term beneficial effect

Table 4. The principal medicines used or in development for the treatment of T2D and their effects on β -cells. DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide 1; IL-1Ra: Interleukine 1 receptor antagonist; SGLT2: Sodium-glucose cotransporter type 2; TZDs: thiazolidinediones.

Reference List

- Abiko, T., Abiko, A., Clermont, A. C. et al., 2003. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. *Diabetes* 52 (3), 829-837.
- ADA, 2010. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 33 Suppl 1, S62-S69.
- Aguilar-Bryan, L., Bryan, J., 1999. Molecular biology of adenosine triphosphate-sensitive potassium channels. *Endocr. Rev.* 20 (2), 101-135.
- Ahren, B., 2011. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? *Curr. Diab. Rep.* 11 (2), 83-90.
- Ainscow, E.K., Zhao, C., Rutter, G. A., 2000. Acute overexpression of lactate dehydrogenase-A perturbs β -cell mitochondrial metabolism and insulin secretion. *Diabetes* 49 (7), 1149-1155.
- Akerfeldt, M.C., Laybutt, D. R., 2011. Inhibition of Id1 augments insulin secretion and protects against high-fat diet-induced glucose intolerance. *Diabetes* 60 (10), 2506-2514.
- Akimoto, Y., Hart, G. W., Wells, L. et al., 2007. Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats. *Glycobiology* 17 (2), 127-140.
- Alarcon, C., Leahy, J. L., Schupp, G. T., Rhodes, C. J., 1995. Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. *J. Clin. Invest* 95 (3), 1032-1039.
- Alarcon, C., Lincoln, B., Rhodes, C. J., 1993. The biosynthesis of the subtilisin-related proprotein convertase PC3, but not that of the PC2 convertase, is regulated by glucose in parallel to proinsulin biosynthesis in rat pancreatic islets. *J. Biol. Chem.* 268 (6), 4276-4280.
- Alarcon, C., Wicksteed, B., Prentki, M., Corkey, B. E., Rhodes, C. J., 2002. Succinate is a preferential metabolic stimulus-coupling signal for glucose-induced proinsulin biosynthesis translation. *Diabetes* 51 (8), 2496-2504.
- Allagnat, F., Christulia, F., Ortis, F. et al., 2010. Sustained production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction and apoptosis. *Diabetologia* 53 (6), 1120-1130.
- Alonso, L.C., Yokoe, T., Zhang, P. et al., 2007. Glucose infusion in mice: a new model to induce β -cell replication. *Diabetes* 56 (7), 1792-1801.
- Andrali, S.S., Sampley, M. L., Vanderford, N. L., Ozcan, S., 2008. Glucose regulation of insulin gene expression in pancreatic β -cells. *Biochem. J.* 415 (1), 1-10.
- Anello, M., Lupi, R., Spampinato, D. et al., 2005. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. *Diabetologia* 48 (2), 282-289.
- Ashcroft, S.J., Sugden, M. C., Williams, I. H., 1980. Carbohydrate metabolism and the glucoreceptor mechanism. *Horm. Metab. Res. Suppl* 10, 1-7.

- Back, S.H., Scheuner, D., Han, J. et al., 2009. Translation attenuation through eIF2 α phosphorylation prevents oxidative stress and maintains the differentiated state in β cells. *Cell Metab* 10 (1), 13-26.
- Bailey, C.J., Gross, J. L., Pieters, A., Bastien, A., List, J. F., 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet* 375 (9733), 2223-2233.
- Banday, A.A., Marwaha, A., Tallam, L. S., Lokhandwala, M. F., 2005. Tempol reduces oxidative stress, improves insulin sensitivity, decreases renal dopamine D1 receptor hyperphosphorylation, and restores D1 receptor-G-protein coupling and function in obese Zucker rats. *Diabetes* 54 (7), 2219-2226.
- Bashan, N., Kovsan, J., Kachko, I., Ovadia, H., Rudich, A., 2009. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. *Physiol Rev.* 89 (1), 27-71.
- Beck-Nielsen, H., Groop, L. C., 1994. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. *J. Clin. Invest* 94 (5), 1714-1721.
- Becker, T.C., BeltrandelRio, H., Noel, R. J., Johnson, J. H., Newgard, C. B., 1994. Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. Enhancement of glucose metabolism and insulin secretion at basal but not stimulatory glucose levels. *J. Biol. Chem.* 269 (33), 21234-21238.
- Benita, Y., Kikuchi, H., Smith, A. D., Zhang, M. Q., Chung, D. C., Xavier, R. J., 2009. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. *Nucleic Acids Res* 37 (14), 4587-4602.
- Bensellam, M., Duvillie, B., Rybachuk, G. et al., 2012. Glucose-induced O₂ consumption activates hypoxia inducible factors 1 and 2 in rat insulin-secreting pancreatic beta-cells. *PLoS ONE.* 7 (1), e29807.
- Bensellam, M., Van Lommel, L., Overbergh, L., Schuit, F. C., Jonas, J. C., 2009. Cluster analysis of rat pancreatic islet gene mRNA levels after culture in low-, intermediate- and high-glucose concentrations. *Diabetologia* 52 (3), 463-476.
- Bernard, C., Berthault, M. F., Saulnier, C., Ktorza, A., 1999. Neogenesis vs. apoptosis As main components of pancreatic β cell mass changes in glucose-infused normal and mildly diabetic adult rats. *FASEB J.* 13 (10), 1195-1205.
- Bindokas, V.P., Kuznetsov, A., Sreenan, S., Polonsky, K. S., Roe, M. W., Philipson, L. H., 2003. Visualizing superoxide production in normal and diabetic rat islets of Langerhans. *J. Biol. Chem.* 278 (11), 9796-9801.
- Bjorklund, A., Bondo, H. J., Falkmer, S., Grill, V., 2004. Openers of ATP-dependent K⁺-channels protect against a signal-transduction-linked and not freely reversible defect of insulin secretion in a rat islet transplantation model of Type 2 diabetes. *Diabetologia* 47 (5), 885-891.
- Bjorklund, A., Grill, V., 1993. B-cell insensitivity in vitro: reversal by diazoxide entails more than one event in stimulus-secretion coupling. *Endocrinology* 132 (3), 1319-1328.
- Blouet, C., Mariotti, F., Azzout-Marniche, D. et al., 2007. Dietary cysteine alleviates sucrose-induced oxidative stress and insulin resistance. *Free Radic. Biol. Med.* 42 (7), 1089-1097.

- Blume, N., Skov, J., Larsson, L. I., Holst, J. J., Madsen, O. D., 1995. Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. *J. Clin. Invest* 96 (5), 2227-2235.
- Boden, G., Shulman, G. I., 2002. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β -cell dysfunction. *Eur. J. Clin. Invest* 32 Suppl 3, 14-23.
- Bonadonna, R.C., Heise, T., Arbet-Engels, C. et al., 2010. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. *J. Clin. Endocrinol. Metab* 95 (11), 5028-5036.
- Bonner-Weir, S., Deery, D., Leahy, J. L., Weir, G. C., 1989. Compensatory growth of pancreatic β -cells in adult rats after short-term glucose infusion. *Diabetes* 38, 49-53.
- Bottino, R., Balamurugan, A. N., Tse, H. et al., 2004. Response of human islets to isolation stress and the effect of antioxidant treatment. *Diabetes* 53 (10), 2559-2568.
- Briaud, I., Rouault, C., Reach, G., Poitout, V., 1999. Long-term exposure of isolated rat islets of Langerhans to supraphysiologic glucose concentrations decreases insulin mRNA levels. *Metabolism* 48 (3), 319-323.
- Bromati, C.R., Lellis-Santos, C., Yamanaka, T. S. et al., 2011. UPR induces transient burst of apoptosis in islets of early lactating rats through reduced AKT phosphorylation via ATF4/CHOP stimulation of TRB3 expression. *Am. J. Physiol Regul. Integr. Comp Physiol* 300 (1), R92-100.
- Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications. *Nature* 414 (6865), 813-820.
- Buchanan, T.A., 2003. Pancreatic β -cell loss and preservation in type 2 diabetes. *Clin. Ther.* 25 Suppl B, B32-B46.
- Bunck, M.C., Diamant, M., Corner, A. et al., 2009. One-year treatment with exenatide improves β -cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care* 32 (5), 762-768.
- Buteau, J., El Assaad, W., Rhodes, C. J., Rosenberg, L., Joly, E., Prentki, M., 2004. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. *Diabetologia* 47 (5), 806-815.
- Butler, A.E., Jang, J., Gurlo, T., Carty, M. D., Soeller, W. C., Butler, P. C., 2004. Diabetes due to a progressive defect in β -cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. *Diabetes* 53 (6), 1509-1516.
- Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., Butler, P. C., 2003. β -cell deficit and increased β -cell apoptosis in humans with type 2 diabetes. *Diabetes* 52 (1), 102-110.
- Campbell, I.W., Mariz, S., 2007. β -cell preservation with thiazolidinediones. *Diabetes Res. Clin. Pract.* 76 (2), 163-176.
- Cantley, J., Selman, C., Shukla, D. et al., 2009. Deletion of the von Hippel-Lindau gene in pancreatic β cells impairs glucose homeostasis in mice. *Journal of Clinical Investigation* 119 (1), 125-135.
- Carlsson, P.O., Andersson, A., Jansson, L., 1996. Pancreatic islet blood flow in normal and obese-hyperglycemic (ob/ob) mice. *Am. J. Physiol* 271 (6 Pt 1), E990-E995.

- Carpenter, L., Mitchell, C. J., Xu, Z. Z., Poronnik, P., Both, G. W., Biden, T. J., 2004. PKC α is activated but not required during glucose-induced insulin secretion from rat pancreatic islets. *Diabetes* 53 (1), 53-60.
- Cavaghan, M.K., Ehrmann, D. A., Byrne, M. M., Polonsky, K. S., 1997. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. *J. Clin. Invest* 100 (3), 530-537.
- Ceriello, A., 2003. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. *Diabetes Care* 26 (5), 1589-1596.
- Chan, C.B., De Leo, D., Joseph, J. W. et al., 2001. Increased uncoupling protein-2 levels in β -cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. *Diabetes* 50 (6), 1302-1310.
- Chan, C.B., MacPhail, R. M., Sheu, L., Wheeler, M. B., Gaisano, H. Y., 1999. β -cell hypertrophy in *fa/fa* rats is associated with basal glucose hypersensitivity and reduced SNARE protein expression. *Diabetes* 48 (5), 997-1005.
- Chang-Chen, K.J., Mullur, R., Bernal-Mizrachi, E., 2008. β -cell failure as a complication of diabetes. *Rev. Endocr. Metab Disord.* 9 (4), 329-343.
- Chen, H., Carlson, E. C., Pellet, L., Moritz, J. T., Epstein, P. N., 2001. Overexpression of metallothionein in pancreatic β -cells reduces streptozotocin-induced DNA damage and diabetes. *Diabetes* 50 (9), 2040-2046.
- Chen, J., Saxena, G., Mungrue, I. N., Lusis, A. J., Shalev, A., 2008. Thioredoxin-interacting protein: a critical link between glucose toxicity and β -cell apoptosis. *Diabetes* 57 (4), 938-944.
- Cheng, K., Ho, K., Stokes, R. et al., 2010. Hypoxia-inducible factor-1 α regulates β cell function in mouse and human islets. *J Clin Invest* 120 (6), 2171-2183.
- Chia, C.W., Egan, J. M., 2008. Incretin-based therapies in type 2 diabetes mellitus. *J. Clin. Endocrinol. Metab* 93 (10), 3703-3716.
- Choi, D., Cai, E. P., Schroer, S. A., Wang, L., Woo, M., 2011. *Vhl* is required for normal pancreatic β cell function and the maintenance of β cell mass with age in mice. *Lab Invest* 91 (4), 527-538.
- Chung, S.S., Kim, M., Lee, J. S. et al., 2011. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β -cells. *Am. J. Physiol Endocrinol. Metab* 301 (5), E912-E921.
- Clark, A., Nilsson, M. R., 2004. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? *Diabetologia* 47 (2), 157-169.
- Clarke, M., Dodson, P. M., 2007. PKC inhibition and diabetic microvascular complications. *Best. Pract. Res. Clin. Endocrinol. Metab* 21 (4), 573-586.
- Cnop, M., Welsh, N., Jonas, J. C., Jorns, A., Lenzen, S., Eizirik, D. L., 2005. Mechanisms of pancreatic β -cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes* 54 (Suppl. 2), S97-S107.
- Cockburn, B.N., Ostrega, D. M., Sturis, J., Kubstrup, C., Polonsky, K. S., Bell, G. I., 1997. Changes in pancreatic islet glucokinase and hexokinase activities with increasing age, obesity, and the onset of diabetes. *Diabetes* 46 (9), 1434-1439.

- Corbett, E.F., Oikawa, K., Francois, P. et al., 1999. Ca^{2+} regulation of interactions between endoplasmic reticulum chaperones. *J. Biol. Chem.* 274 (10), 6203-6211.
- Coskun, O., Kanter, M., Korkmaz, A., Oter, S., 2005. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β -cell damage in rat pancreas. *Pharmacol. Res.* 51 (2), 117-123.
- Costes, S., Broca, C., Bertrand, G. et al., 2006. ERK1/2 control phosphorylation and protein level of cAMP-responsive element-binding protein: a key role in glucose-mediated pancreatic β -cell survival. *Diabetes* 55 (8), 2220-2230.
- Costes, S., Huang, C. J., Gurlo, T. et al., 2011. β -cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency. *Diabetes* 60 (1), 227-238.
- Coughlan, M.T., Yap, F. Y., Tong, D. C. et al., 2011. Advanced glycation end products are direct modulators of β -cell function. *Diabetes* 60 (10), 2523-2532.
- D'Alessandris, C., Andreozzi, F., Federici, M. et al., 2004. Increased *O*-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic β -cells. *FASEB J.* 18 (9), 959-961.
- DasEvcimen, N., King, G. L., 2007. The role of protein kinase C activation and the vascular complications of diabetes. *Pharmacol. Res.* 55 (6), 498-510.
- De Vroede, M.A., Veld, P. A., Pipeleers, D. G., 1990. Deoxyribonucleic acid synthesis in cultured adult rat pancreatic β cells. *Endocrinology* 127 (3), 1510-1516.
- DeFronzo, R.A., Davidson, J. A., Del, P. S., 2012. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. *Diabetes Obes. Metab* 14 (1), 5-14.
- Delepine, M., Nicolino, M., Barrett, T., Golamaully, M., Lathrop, G. M., Julier, C., 2000. EIF2AK3, encoding translation initiation factor 2- α kinase 3, is mutated in patients with Wolcott-Rallison syndrome. *Nat. Genet.* 25 (4), 406-409.
- DelGuerra, S., Grupillo, M., Masini, M. et al., 2007. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. *Diabetes Metab Res. Rev.* 23 (3), 234-238.
- DelGuerra, S., Lupi, R., Marselli, L. et al., 2005. Functional and molecular defects of pancreatic islets in human type 2 diabetes. *Diabetes* 54 (3), 727-735.
- Deng, S., Vatamaniuk, M., Huang, X. et al., 2004. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. *Diabetes* 53 (3), 624-632.
- Diani, A.R., Sawada, G., Wyse, B., Murray, F. T., Khan, M., 2004. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. *Am. J. Physiol Endocrinol. Metab* 286 (1), E116-E122.
- Dixit, P.P., Misar, A., Mujumdar, A. M., Ghaskadbi, S., 2010. Pre-treatment of Syndrex protects mice from becoming diabetic after streptozotocin injection. *Fitoterapia* 81 (5), 403-412.
- Donath, M.Y., Gross, D. J., Cerasi, E., Kaiser, N., 1999. Hyperglycemia-induced β -cell apoptosis in pancreatic islets of *Psammomys obesus* during development of diabetes. *Diabetes* 48 (4), 738-744.
- Donath, M.Y., Shoelson, S. E., 2011. Type 2 diabetes as an inflammatory disease. *Nat. Rev. Immunol.* 11 (2), 98-107.

- Drucker, D.J., 2006. The biology of incretin hormones. *Cell Metab* 3 (3), 153-165.
- Dubois, M., Vacher, P., Roger, B. et al., 2007. Glucotoxicity inhibits late steps of insulin exocytosis. *Endocrinology* 148 (4), 1605-1614.
- Efanova, I.B., Zaitsev, S. V., Zhivotovsky, B. et al., 1998. Glucose and tolbutamide induce apoptosis in pancreatic β -cells. A process dependent on intracellular Ca^{2+} concentration. *J. Biol. Chem.* 273 (50), 33501-33507.
- Ehses, J.A., Lacraz, G., Giroix, M. H. et al., 2009. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. *Proc Natl Acad Sci U. S A* 106 (33), 13998-14003.
- Ehses, J.A., Perren, A., Eppler, E. et al., 2007. Increased number of islet-associated macrophages in type 2 diabetes. *Diabetes* 56 (9), 2356-2370.
- Eiki, J., Nagata, Y., Futamura, M. et al., 2011. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. *Mol. Pharmacol.* 80 (6), 1156-1165.
- Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., Butler, P. C., 2011. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. *Gastroenterology* 141 (1), 150-156.
- Eliasson, L., Renstrom, E., Ammala, C. et al., 1996. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic β cells. *Science* 271 (5250), 813-815.
- Elouil, H., Bensellam, M., Guiot, Y. et al., 2007. Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets. *Diabetologia* 50 (7), 1442-1452.
- Elouil, H., Cardozo, A. K., Eizirik, D. L., Henquin, J. C., Jonas, J. C., 2005. High glucose and hydrogen peroxide increase c-Myc and haeme-oxygenase 1 mRNA levels in rat pancreatic islets without activating NF κ B. *Diabetologia* 48 (3), 496-505.
- Elvidge, G.P., Glenney, L., Appelhoff, R. J., Ratcliffe, P. J., Ragoussis, J., Gleadle, J. M., 2006. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1 α , HIF-2 α , and other pathways. *J. Biol. Chem.* 281 (22), 15215-15226.
- Esguerra, J.L., Bolmeson, C., Cilio, C. M., Eliasson, L., 2011. Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat. *PLoS. ONE.* 6 (4), e18613.
- Eto, K., Tsubamoto, Y., Terauchi, Y. et al., 1999. Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. *Science* 283 (5404), 981-985.
- Evans, J.L., 2007. Antioxidants: do they have a role in the treatment of insulin resistance? *Indian J. Med. Res.* 125 (3), 355-372.
- Evans, J.L., Goldfine, I. D., Maddux, B. A., Grodsky, G. M., 2002. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Endocr. Rev.* 23 (5), 599-622.
- Farilla, L., Hui, H., Bertolotto, C. et al., 2002. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. *Endocrinology* 143 (11), 4397-4408.

- Favaro, E., Miceli, I., Bussolati, B. et al., 2008. Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway. *Am. J. Pathol.* 173 (2), 442-450.
- Federici, M., Hribal, M., Perego, L. et al., 2001. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. *Diabetes* 50 (6), 1290-1301.
- Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., List, J. F., 2010. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* 33 (10), 2217-2224.
- Finegood, D.T., McArthur, M. D., Kojwang, D. et al., 2001. β -cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. *Diabetes* 50 (5), 1021-1029.
- Fiordaliso, F., Bianchi, R., Staszewsky, L. et al., 2004. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. *J. Mol. Cell Cardiol.* 37 (5), 959-968.
- Flamez, D., Berger, V., Kruhoffer, M., Orntoft, T., Pipeleers, D., Schuit, F. C., 2002. Critical role for cataplerosis via citrate in glucose-regulated insulin release. *Diabetes* 51 (7), 2018-2024.
- Friedland, S.N., Leong, A., Fillion, K. B. et al., 2012. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. *Am. J. Med.* 125 (2), 126-133.
- Fujimori, Y., Katsuno, K., Nakashima, I., Ishikawa-Takemura, Y., Fujikura, H., Isaji, M., 2008. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. *J Pharmacol Exp Ther* 327 (1), 268-276.
- Fujimori, Y., Katsuno, K., Ojima, K. et al., 2009. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. *Eur. J. Pharmacol.* 609 (1-3), 148-154.
- Futamura, M., Yao, J., Li, X. et al., 2012. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. *Diabetologia* 55 (4), 1071-1080.
- Fyfe, M.C., White, J. R., Taylor, A. et al., 2007. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. *Diabetologia* 50 (6), 1277-1287.
- Gadot, M., Ariav, Y., Cerasi, E., Kaiser, N., Gross, D. J., 1995. Hyperproinsulinemia in the diabetic *Psammomys obesus* is a result of increased secretory demand on the beta-cell. *Endocrinology* 136 (10), 4218-4223.
- Gadot, M., Leibowitz, G., Shafrir, E., Cerasi, E., Gross, D. J., Kaiser, N., 1994. Hyperproinsulinemia and insulin deficiency in the diabetic *Psammomys obesus*. *Endocrinology* 135 (2), 610-616.
- Gaisano, H.Y., Ostenson, C. G., Sheu, L., Wheeler, M. B., Efendic, S., 2002. Abnormal expression of pancreatic islet exocytotic soluble N-ethylmaleimide-sensitive factor attachment protein receptors in Goto-Kakizaki rats is partially restored by phlorizin treatment and accentuated by high glucose treatment. *Endocrinology* 143 (11), 4218-4226.
- Gao, Z., Young, R. A., Li, G. et al., 2003. Distinguishing features of leucine and α -ketoisocaproate sensing in pancreatic β -cells. *Endocrinology* 144 (5), 1949-1957.

- Garcia-Barrado, M.J., Jonas, J. C., Gilon, P., Henquin, J. C., 1996. Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca^{2+} in pancreatic B-cells. *Eur. J. Pharmacol.* 298 (3), 279-286.
- Garvey, W.T., Olefsky, J. M., Griffin, J., Hamman, R. F., Kolterman, O. G., 1985. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. *Diabetes* 34 (3), 222-234.
- Gelebart, P., Opas, M., Michalak, M., 2005. Calreticulin, a Ca^{2+} -binding chaperone of the endoplasmic reticulum. *Int. J. Biochem. Cell Biol.* 37 (2), 260-266.
- Gerstein, H.C., Yusuf, S., Bosch, J. et al., 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. *Lancet* 368 (9541), 1096-1105.
- Ghanaat-Pour, H., Huang, Z., Lehtihet, M., Sjöholm, A., 2007. Global expression profiling of glucose-regulated genes in pancreatic islets of spontaneously diabetic Goto-Kakizaki rats. *J. Mol. Endocrinol.* 39 (2), 135-150.
- Gier, B., Krippeit-Drews, P., Sheiko, T. et al., 2009. Suppression of K_{ATP} channel activity protects murine pancreatic β cells against oxidative stress. *J. Clin. Invest* 119 (11), 3246-3256.
- Gilbert, M., Jung, S. R., Reed, B. J., Sweet, I. R., 2008. Islet oxygen consumption and insulin secretion tightly coupled to calcium derived from L-type calcium channels but not from the endoplasmic reticulum. *J Biol Chem* 283 (36), 24334-24342.
- Gill, D., Brocklehurst, K. J., Brown, H. W., Smith, D. M., 2011. Upregulation of β -cell genes and improved function in rodent islets following chronic glucokinase activation. *J. Mol. Endocrinol.* 47 (1), 59-67.
- Gilligan, M., Welsh, G. I., Flynn, A. et al., 1996. Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans. *J. Biol. Chem.* 271 (4), 2121-2125.
- Glaser, B., Leibovich, G., Nesher, R., Hartling, S., Binder, C., Cerasi, E., 1988. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. *Acta Endocrinol. (Copenh)* 118 (3), 365-373.
- Gleason, C.E., Gonzalez, M., Harmon, J. S., Robertson, R. P., 2000. Determinants of glucose toxicity and its reversibility in the pancreatic islet β -cell line, HIT-T15. *Am. J. Physiol Endocrinol. Metab* 279 (5), E997-1002.
- Gomez, E., Powell, M. L., Greenman, I. C., Herbert, T. P., 2004. Glucose-stimulated protein synthesis in pancreatic β -cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 α . *J. Biol. Chem.* 279 (52), 53937-53946.
- Gormley, M.J., Hadden, D. R., Woods, R., Sheridan, B., Andrews, W. J., 1986. One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal. *Metabolism* 35 (11), 1029-1036.
- Gorogawa, S., Kajimoto, Y., Umayahara, Y. et al., 2002. Probucol preserves pancreatic β -cell function through reduction of oxidative stress in type 2 diabetes. *Diabetes Res. Clin. Pract.* 57 (1), 1-10.

- Greenman, I.C., Gomez, E., Moore, C. E., Herbert, T. P., 2005. The selective recruitment of mRNA to the ER and an increase in initiation are important for glucose-stimulated proinsulin synthesis in pancreatic β -cells. *Biochem J* 391 (Pt 2), 291-300.
- Greenman, I.C., Gomez, E., Moore, C. E., Herbert, T. P., 2007. Distinct glucose-dependent stress responses revealed by translational profiling in pancreatic β -cells. *J Endocrinol* 192 (1), 179-187.
- Greig, N.H., Holloway, H. W., De Ore, K. A. et al., 1999. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. *Diabetologia* 42 (1), 45-50.
- Grill, V., Bjorklund, A., 2009. Impact of metabolic abnormalities for β cell function: clinical significance and underlying mechanisms. *Mol. Cell Endocrinol.* 297 (1-2), 86-92.
- Grimaldi, K.A., Siddle, K., Hutton, J. C., 1987. Biosynthesis of insulin secretory granule membrane proteins. Control by glucose. *Biochem. J.* 245 (2), 567-573.
- Grimmsmann, T., Rustenbeck, I., 1998. Direct effects of diazoxide on mitochondria in pancreatic β -cells and on isolated liver mitochondria. *Br. J. Pharmacol.* 123 (5), 781-788.
- Guest, P.C., Bailyes, E. M., Hutton, J. C., 1997. Endoplasmic reticulum Ca^{2+} is important for the proteolytic processing and intracellular transport of proinsulin in the pancreatic β -cell. *Biochem. J.* 323 (Pt 2), 445-450.
- Guest, P.C., Rhodes, C. J., Hutton, J. C., 1989. Regulation of the biosynthesis of insulin-secretory-granule proteins. Co-ordinate translational control is exerted on some, but not all, granule matrix constituents. *Biochem. J.* 257 (2), 431-437.
- Guldstrand, M., Grill, V., Bjorklund, A., Lins, P. E., Adamson, U., 2002. Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. *Diabetes Metab* 28 (6 Pt 1), 448-456.
- Gunton, J.E., Kulkarni, R. N., Yim, S. et al., 2005. Loss of *ARNT/HIF1 β* Mediates Altered Gene Expression and Pancreatic-Islet Dysfunction in Human Type 2 Diabetes. *Cell* 122 (3), 337-349.
- Gupta, D., Kono, T., Evans-Molina, C., 2010. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. *Diabetes Obes. Metab* 12 (12), 1036-1047.
- Gurlo, T., Ryazantsev, S., Huang, C. J. et al., 2010. Evidence for proteotoxicity in β cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. *Am. J. Pathol.* 176 (2), 861-869.
- Haataja, L., Gurlo, T., Huang, C. J., Butler, P. C., 2008. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. *Endocr. Rev.* 29 (3), 303-316.
- Han, D., Lerner, A. G., Vande, W. L. et al., 2009. IRE1 α kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. *Cell* 138 (3), 562-575.
- Harding, H.P., Zhang, Y., Zeng, H. et al., 2003. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. *Mol. Cell* 11 (3), 619-633.
- Harmon, J.S., Bogdani, M., Parazzoli, S. D. et al., 2009. β -Cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice. *Endocrinology* 150 (11), 4855-4862.

- Harmon, J.S., Gleason, C. E., Tanaka, Y., Poitout, V., Robertson, R. P., 2001. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. *Diabetes* 50 (11), 2481-2486.
- Harmon, J.S., Stein, R., Robertson, R. P., 2005. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. *J. Biol. Chem.* 280 (12), 11107-11113.
- Harmon, J.S., Tanaka, Y., Olson, L. K., Robertson, R. P., 1998. Reconstitution of glucotoxic HIT-T15 cells with somatostatin transcription factor-1 partially restores insulin promoter activity. *Diabetes* 47 (6), 900-904.
- Harrison, L.B., Adams-Huet, B., Raskin, P., Lingvay, I., 2012. β -Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. *Diabetes Care* 35 (7), 1406-1412.
- Harrower, A.D., 1994. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. *J. Diabetes Complications* 8 (4), 201-203.
- Hartman, M.G., Lu, D., Kim, M. L. et al., 2004. Role for activating transcription factor 3 in stress-induced β -cell apoptosis. *Mol. Cell Biol.* 24 (13), 5721-5732.
- Heinis, M., Simon, M. T., Ilc, K. et al., 2010. Oxygen tension regulates pancreatic β -cell differentiation through hypoxia-inducible factor 1 α . *Diabetes* 59 (3), 662-669.
- Henquin, J.C., 2000. Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes* 49 (11), 1751-1760.
- Henquin, J.C., Ravier, M. A., Nenquin, M., Jonas, J. C., Gilon, P., 2003. Hierarchy of the β -cell signals controlling insulin secretion. *Eur. J. Clin. Invest* 33 (9), 742-750.
- Higa, M., Zhou, Y. T., Ravazzola, M., Baetens, D., Orci, L., Unger, R. H., 1999. Troglitazone prevents mitochondrial alterations, β cell destruction, and diabetes in obese prediabetic rats. *Proc. Natl. Acad. Sci. U. S. A* 96 (20), 11513-11518.
- Hinke, S.A., Hellemans, K., Schuit, F. C., 2004. Plasticity of the β cell insulin secretory competence: preparing the pancreatic β cell for the next meal. *J. Physiol* 558 (Pt 2), 369-380.
- Hofmann, S.M., Dong, H. J., Li, Z. et al., 2002. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. *Diabetes* 51 (7), 2082-2089.
- Homo-Delarche, F., Calderari, S., Irminger, J. C. et al., 2006. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. *Diabetes* 55 (6), 1625-1633.
- Hoorens, A., Van de Casteele, M., Klöppel, G., Pipeleers, D. G., 1996. Glucose promotes survival of rat pancreatic β cells by activating synthesis of proteins which suppress a constitutive apoptotic program. *J. Clin. Invest.* 98, 1568-1574.
- Hosokawa, H., Hosokawa, Y. A., Leahy, J. L., 1995. Upregulated hexokinase activity in isolated islets from diabetic 90% pancreatectomized rats. *Diabetes* 44 (11), 1328-1333.
- Hotta, M., Tashiro, F., Ikegami, H. et al., 1998. Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. *J. Exp. Med.* 188 (8), 1445-1451.
- Hou, N., Torii, S., Saito, N., Hosaka, M., Takeuchi, T., 2008a. Reactive oxygen species-mediated pancreatic β -cell death is regulated by interactions between stress-activated protein

kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated protein kinase phosphatases. *Endocrinology* 149 (4), 1654-1665.

Hou, Z.Q., Li, H. L., Gao, L., Pan, L., Zhao, J. J., Li, G. W., 2008b. Involvement of chronic stresses in rat islet and INS-1 cell glucotoxicity induced by intermittent high glucose. *Mol. Cell Endocrinol.* 291 (1-2), 71-78.

Housley, M.P., Rodgers, J. T., Udeshi, N. D. et al., 2008. O-GlcNAc regulates FoxO activation in response to glucose. *J. Biol. Chem.* 283 (24), 16283-16292.

Houstis, N., Rosen, E. D., Lander, E. S., 2006. Reactive oxygen species have a causal role in multiple forms of insulin resistance. *Nature* 440 (7086), 944-948.

Huang, C.J., Lin, C. Y., Haataja, L. et al., 2007a. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated β -cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. *Diabetes* 56 (8), 2016-2027.

Huang, Q., Bu, S., Yu, Y. et al., 2007b. Diazoxide prevents diabetes through inhibiting pancreatic β -cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase. *Endocrinology* 148 (1), 81-91.

Huebschmann, A.G., Regensteiner, J. G., Vlassara, H., Reusch, J. E., 2006. Diabetes and advanced glycoxidation end products. *Diabetes Care* 29 (6), 1420-1432.

Hugl, S.R., White, M. F., Rhodes, C. J., 1998. Insulin-like growth factor I (IGF-I)-stimulated pancreatic β -cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. *J. Biol. Chem.* 273 (28), 17771-17779.

Hung, Y.J., Hsieh, C. H., Pei, D. et al., 2005. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. *Clin. Endocrinol. (Oxf)* 62 (1), 85-91.

Huseini, H.F., Larijani, B., Heshmat, R. et al., 2006. The efficacy of *Silybum marianum* (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. *Phytother. Res.* 20 (12), 1036-1039.

Hussain, S.A., 2007. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. *J. Med. Food* 10 (3), 543-547.

Ihara, Y., Toyokuni, S., Uchida, K. et al., 1999. Hyperglycemia causes oxidative stress in pancreatic β -cells of GK rats, a model of type 2 diabetes. *Diabetes* 48 (4), 927-932.

Ihara, Y., Yamada, Y., Toyokuni, S. et al., 2000. Antioxidant α -tocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes. *FEBS Lett.* 473 (1), 24-26.

Ishigaki, S., Fonseca, S. G., Osowski, C. M. et al., 2010. AATF mediates an antiapoptotic effect of the unfolded protein response through transcriptional regulation of AKT1. *Cell Death. Differ.* 17 (5), 774-786.

Ishihara, H., Asano, T., Tsukuda, K. et al., 1994. Overexpression of hexokinase I but not GLUT1 glucose transporter alters concentration dependence of glucose-stimulated insulin secretion in pancreatic β -cell line MIN6. *J. Biol. Chem.* 269 (4), 3081-3087.

Ishii, H., Jirousek, M. R., Koya, D. et al., 1996. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. *Science* 272, 728-731.

- Israili, Z.H., 2011. Advances in the treatment of type 2 diabetes mellitus. *Am. J. Ther.* 18 (2), 117-152.
- Itoh, N., Okamoto, H., 1980. Translational control of proinsulin synthesis by glucose. *Nature* 283 (5742), 100-102.
- Itoh, N., Sei, T., Nose, K., Okamoto, H., 1978. Glucose stimulation of the proinsulin synthesis in isolated pancreatic islets without increasing amount of proinsulin mRNA. *FEBS Lett.* 93 (2), 343-347.
- Iwashima, Y., Kondoh-Abiko, A., Seino, S. et al., 1994. Reduced levels of messenger ribonucleic acid for calcium channel, glucose transporter-2, and glucokinase are associated with alterations in insulin secretion in fasted rats. *Endocrinology* 135 (3), 1010-1017.
- Iyer, S.N., Drake, A. J., III, West, R. L., Mendez, C. E., Tanenberg, R. J., 2012. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. *Endocr. Pract.* 18 (1), e10-e13.
- Janson, J., Ashley, R. H., Harrison, D., McIntyre, S., Butler, P. C., 1999. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. *Diabetes* 48, 491-498.
- Jennings, P.E., Belch, J. J., 2000. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide. *Metabolism* 49 (2 Suppl 1), 23-26.
- Jermendy, A., Toschi, E., Aye, T. et al., 2011. Rat neonatal beta cells lack the specialised metabolic phenotype of mature beta cells. *Diabetologia* 54 (3), 594-604.
- Jetton, T.L., Everill, B., Lausier, J. et al., 2008. Enhanced β -cell mass without increased proliferation following chronic mild glucose infusion. *Am. J. Physiol Endocrinol. Metab* 294 (4), E679-E687.
- Jitrapakdee, S., Wutthisathapornchai, A., Wallace, J. C., MacDonald, M. J., 2010. Regulation of insulin secretion: role of mitochondrial signalling. *Diabetologia* 53 (6), 1019-1032.
- Johnson, D., Shepherd, R. M., Gill, D., Gorman, T., Smith, D. M., Dunne, M. J., 2007. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. *Diabetes* 56 (6), 1694-1702.
- Jonas, J.C., Bensellam, M., Duprez, J., Elouil, H., Guiot, Y., Pascal, S. M., 2009. Glucose regulation of islet stress responses and β -cell failure in type 2 diabetes. *Diabetes Obes. Metab* 11 Suppl 4, 65-81.
- Jonas, J.C., Guiot, Y., Rahier, J., Henquin, J. C., 2003. Haeme-oxygenase 1 expression in rat pancreatic β -cells is stimulated by supraphysiological glucose concentrations and by cyclic AMP. *Diabetologia* 46 (9), 1234-1244.
- Jonas, J.C., Laybutt, R., Steil, G. M., Trivedi, N., Weir, G. C., Henquin, J. C., 2001. Potential role of the early response gene c-myc in β -cell adaptation to changes in glucose concentration. *Diabetes* 50 Suppl 1, S137.
- Jonas, J.C., Sharma, A., Hasenkamp, W. et al., 1999. Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes. *J. Biol. Chem.* 274 (20), 14112-14121.
- Jung, S.K., Kauri, L. M., Qian, W. J., Kennedy, R. T., 2000. Correlated oscillations in glucose consumption, oxygen consumption, and intracellular free Ca^{2+} in single islets of Langerhans. *J Biol Chem* 275 (9), 6642-6650.

- Jung, S.R., Reed, B. J., Sweet, I. R., 2009. A highly energetic process couples calcium influx through L-type calcium channels to insulin secretion in pancreatic β -cells. *Am J Physiol Endocrinol Metab* 297 (3), E717-E727.
- Jurczak, M.J., Lee, H. Y., Birkenfeld, A. L. et al., 2011. SGLT2 deletion improves glucose homeostasis and preserves pancreatic β -cell function. *Diabetes* 60 (3), 890-898.
- Kahn, S.E., 2003. The relative contributions of insulin resistance and β -cell dysfunction to the pathophysiology of Type 2 diabetes. *Diabetologia* 46 (1), 3-19.
- Kaiser, N., Corcos, A. P., Sarel, I., Cerasi, E., 1991. Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. *Endocrinology* 129 (4), 2067-2076.
- Kaneto, H., Fujii, J., Myint, T. et al., 1996. Reducing sugars trigger oxidative modification and apoptosis in pancreatic β -cells by provoking oxidative stress through the glycation reaction. *Biochem. J.* 320 (Pt 3), 855-863.
- Kaneto, H., Kajimoto, Y., Miyagawa, J. et al., 1999. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β -cells against glucose toxicity. *Diabetes* 48 (12), 2398-2406.
- Kaneto, H., Sharma, A., Suzuma, K. et al., 2002a. Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation. *J. Biol. Chem.* 277 (15), 12998-13006.
- Kaneto, H., Suzuma, K., Sharma, A., Bonner-Weir, S., King, G. L., Weir, G. C., 2002b. Involvement of protein kinase C β 2 in c-myc induction by high glucose in pancreatic β -cells. *J. Biol. Chem.* 277 (5), 3680-3685.
- Kaneto, H., Xu, G., Fujii, N., Kim, S., Bonner-Weir, S., Weir, G. C., 2002c. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. *J. Biol. Chem.* 277 (33), 30010-30018.
- Kaneto, H., Xu, G., Song, K. H. et al., 2001. Activation of the hexosamine pathway leads to deterioration of pancreatic β -cell function through the induction of oxidative stress. *J. Biol. Chem.* 276 (33), 31099-31104.
- Kanter, M., Coskun, O., Korkmaz, A., Oter, S., 2004. Effects of *Nigella sativa* on oxidative stress and β -cell damage in streptozotocin-induced diabetic rats. *Anat. Rec. A Discov. Mol. Cell Evol. Biol.* 279 (1), 685-691.
- Kassis, N., Bernard, C., Pusterla, A. et al., 2000. Correlation between pancreatic islet uncoupling protein-2 (UCP2) mRNA concentration and insulin status in rats. *Int. J. Exp. Diabetes Res.* 1 (3), 185-193.
- Katsuno, K., Fujimori, Y., Ishikawa-Takemura, Y., Isaji, M., 2009. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK- A^y mice. *Eur. J Pharmacol* 618 (1-3), 98-104.
- Kaufman, R.J., Back, S. H., Song, B., Han, J., Hassler, J., 2010. The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β -cells. *Diabetes Obes. Metab* 12 Suppl 2, 99-107.
- Kaushik, S., Singh, R., Cuervo, A. M., 2010. Autophagic pathways and metabolic stress. *Diabetes Obes. Metab* 12 Suppl 2, 4-14.

- Kautz, S., van, B. L., Schuster, M., Wolf, E., Wanke, R., Herbach, N., 2012. Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich *Ins2^{C95S}*). *Diabetologia* 55 (2), 382-391.
- Kawamori, D., Kajimoto, Y., Kaneto, H. et al., 2003. Oxidative stress induces nucleocytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH₂-terminal kinase. *Diabetes* 52 (12), 2896-2904.
- Khalidi, M.Z., Elouil, H., Guiot, Y., Henquin, J. C., Jonas, J. C., 2006. The antioxidants N-acetyl-L-cysteine and manganese(III)tetrakis (4-benzoic acid)porphyrin do not prevent β -cell dysfunction in rat islets cultured in high glucose for 1 wk. *Am J Physiol Endocrinol Metab* 291, E137-E146.
- Khalidi, M.Z., Guiot, Y., Gilon, P., Henquin, J. C., Jonas, J. C., 2004. Increased glucose sensitivity of both triggering and amplifying pathways of insulin secretion in rat islets cultured for one week in high glucose. *Am. J. Physiol. Endocrinol. Metab.* 287, E207-E217.
- Khamaisi, M., Rudich, A., Beeri, I. et al., 1999. Metabolic effects of γ -linolenic acid- α -lipoic acid conjugate in streptozotocin diabetic rats. *Antioxid. Redox. Signal.* 1 (4), 523-535.
- Kim, W., Hudson, B. I., Moser, B. et al., 2005. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. *Ann. N. Y. Acad. Sci.* 1043, 553-561.
- Kimoto, K., Suzuki, K., Kizaki, T. et al., 2003. Gliclazide protects pancreatic β -cells from damage by hydrogen peroxide. *Biochem. Biophys. Res. Commun.* 303 (1), 112-119.
- King, G.L., 2008. The role of inflammatory cytokines in diabetes and its complications. *J. Periodontol.* 79 (8 Suppl), 1527-1534.
- Kitabchi, A.E., Tempresa, M., Knowler, W. C. et al., 2005. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. *Diabetes* 54 (8), 2404-2414.
- Kjorholt, C., Akerfeldt, M. C., Biden, T. J., Laybutt, D. R., 2005. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of β -cell differentiation and secretory function in the *db/db* mouse model of diabetes. *Diabetes* 54 (9), 2755-2763.
- Kluth, O., Mirhashemi, F., Scherneck, S. et al., 2011. Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. *Diabetologia* 54 (3), 605-616.
- Knowler, W.C., Barrett-Connor, E., Fowler, S. E. et al., 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* 346 (6), 393-403.
- Knowler, W.C., Hamman, R. F., Edelstein, S. L. et al., 2005. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. *Diabetes* 54 (4), 1150-1156.
- Knutson, K.L., Hoenig, M., 1994. Identification and subcellular characterization of protein kinase-C isoforms in insulinoma beta-cells and whole islets. *Endocrinology* 135 (3), 881-886.
- Ko, S.H., Kwon, H. S., Kim, S. R. et al., 2004. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. *Biochem. Biophys. Res. Commun.* 316 (1), 114-122.
- Kolb, H., Mandrup-Poulsen, T., 2005. An immune origin of type 2 diabetes? *Diabetologia* 48 (6), 1038-1050.

- Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., Pfister, M., 2009. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. *Clin Pharmacol Ther* 85 (5), 513-519.
- Kosaka, K., Kuzuya, T., Akanuma, Y., Hagura, R., 1980. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. *Diabetologia* 18 (1), 23-28.
- Koya, D., Haneda, M., Nakagawa, H. et al., 2000. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. *FASEB J.* 14 (3), 439-447.
- Koya, D., Lee, I. K., Ishii, H., Kanoh, H., King, G. L., 1997. Prevention of glomerular dysfunction in diabetic rats by treatment with d- α -tocopherol. *J. Am. Soc. Nephrol.* 8 (3), 426-435.
- Krippeit-Drews, P., Kramer, C., Welker, S., Lang, F., Ammon, H. P., Drews, G., 1999. Interference of H₂O₂ with stimulus-secretion coupling in mouse pancreatic β -cells. *J. Physiol* 514 (Pt 2), 471-481.
- Kuo, M., Zilberfarb, V., Gangneux, N., Christeff, N., Issad, T., 2008. O-glycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene. *FEBS Lett.* 582 (5), 829-834.
- Kvezereli, M., Vallentin, A., Mochly-Rosen, D., Busque, S., Fontaine, M. J., 2008. Islet cell survival during isolation improved through protein kinase C epsilon activation. *Transplant. Proc.* 40 (2), 375-378.
- Kwon, G., Marshall, C. A., Liu, H., Pappan, K. L., Remedi, M. S., McDaniel, M. L., 2006. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by K_{ATP} channels: effects on cell cycle progression in rodent islets. *J. Biol. Chem.* 281 (6), 3261-3267.
- Lacraz, G., Figeac, F., Movassat, J. et al., 2009a. Diabetic β -cells can achieve self-protection against oxidative stress through an adaptive up-regulation of their antioxidant defenses. *PLoS ONE.* 4 (8), e6500.
- Lacraz, G., Figeac, F., Movassat, J., Kassis, N., Portha, B., 2010. Diabetic GK/Par rat β -cells are spontaneously protected against H₂O₂-triggered apoptosis. A cAMP-dependent adaptive response. *Am. J. Physiol Endocrinol. Metab* 298 (1), E17-E27.
- Lacraz, G., Giroix, M. H., Kassis, N. et al., 2009b. Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. *PLoS ONE.* 4 (9), e6963.
- Ladiges, W.C., Knoblaugh, S. E., Morton, J. F. et al., 2005. Pancreatic β -cell failure and diabetes in mice with a deletion mutation of the endoplasmic reticulum molecular chaperone gene P58^{IPK}. *Diabetes* 54 (4), 1074-1081.
- Larsen, C.M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., Mandrup-Poulsen, T., 2009. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. *Diabetes Care* 32 (9), 1663-1668.
- Larsen, C.M., Faulenbach, M., Vaag, A. et al., 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N. Engl. J. Med.* 356 (15), 1517-1526.

- Laybutt, D.R., Glandt, M., Xu, G. et al., 2003. Critical reduction in β -cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. *J. Biol. Chem.* 278 (5), 2997-3005.
- Laybutt, D.R., Hawkins, Y. C., Lock, J. et al., 2007a. Influence of diabetes on the loss of beta cell differentiation after islet transplantation in rats. *Diabetologia* 50 (10), 2117-2125.
- Laybutt, D.R., Kaneto, H., Hasenkamp, W. et al., 2002a. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to β -cell survival during chronic hyperglycemia. *Diabetes* 51 (2), 413-423.
- Laybutt, D.R., Preston, A. M., Akerfeldt, M. C. et al., 2007b. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. *Diabetologia* 50 (4), 752-763.
- Laybutt, D.R., Sharma, A., Sgroi, D. C., Gaudet, J., Bonner-Weir, S., Weir, G. C., 2002b. Genetic regulation of metabolic pathways in β -cells disrupted by hyperglycemia. *J. Biol. Chem.* 277 (13), 10912-10921.
- Laybutt, D.R., Weir, G. C., Kaneto, H. et al., 2002c. Overexpression of c-Myc in β -cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. *Diabetes* 51 (6), 1793-1804.
- Lee, B.W., Chae, H. Y., Kwon, S. J., Park, S. Y., Ihm, J., Ihm, S. H., 2010. RAGE ligands induce apoptotic cell death of pancreatic β -cells via oxidative stress. *Int. J. Mol. Med.* 26 (6), 813-818.
- Leibowitz, G., Ferber, S., Apelqvist, A. et al., 2001. IPF1/PDX1 deficiency and β -cell dysfunction in *Psammomys obesus*, an animal with type 2 diabetes. *Diabetes* 50 (8), 1799-1806.
- Leibowitz, G., Oprescu, A. I., Uckaya, G., Gross, D. J., Cerasi, E., Kaiser, N., 2003. Insulin does not mediate glucose stimulation of proinsulin biosynthesis. *Diabetes* 52 (4), 998-1003.
- Lenzen, S., Drinkgern, J., Tiedge, M., 1996. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. *Free Radic. Biol. Med.* 20 (3), 463-466.
- Lenzen, S., Panten, U., 1983. Characterization of succinate dehydrogenase and alpha-glycerophosphate dehydrogenase in pancreatic islets. *Biochem. Med.* 30 (3), 349-356.
- Li, D., Yin, X., Zmuda, E. J. et al., 2008. The repression of IRS2 gene by ATF3, a stress-inducible gene, contributes to pancreatic β -cell apoptosis. *Diabetes* 57 (3), 635-644.
- Li, J., Wang, J. J., Yu, Q., Wang, M., Zhang, S. X., 2009. Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy. *FEBS Lett.* 583 (9), 1521-1527.
- Li, X., Zhang, L., Meshinchi, S. et al., 2006. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. *Diabetes* 55 (11), 2965-2973.
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., Drucker, D. J., 2003. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. *J. Biol. Chem.* 278 (1), 471-478.
- Li, Y., Xu, W., Liao, Z. et al., 2004. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β -cell function. *Diabetes Care* 27 (11), 2597-2602.
- Liew, C.W., Bochenski, J., Kawamori, D. et al., 2010. The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse β cells. *J. Clin. Invest* 120 (8), 2876-2888.

- Lim, S., Rashid, M. A., Jang, M. et al., 2011. Mitochondria-targeted antioxidants protect pancreatic β -cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity. *Cell Physiol Biochem*. 28 (5), 873-886.
- Lin, C.Y., Gurlo, T., Kaye, R. et al., 2007. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced β -cell apoptosis in h-IAPP transgenic mice. *Diabetes* 56 (5), 1324-1332.
- Lin, N., Zhang, H., Su, Q., 2012. Advanced glycation end-products induce injury to pancreatic beta cells through oxidative stress. *Diabetes Metab* .
- Lindenmeyer, M.T., Rastaldi, M. P., Ikehata, M. et al., 2008. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. *J. Am. Soc. Nephrol*. 19 (11), 2225-2236.
- Ling, Z., Hannaert, J. C., Pipeleers, D., 1994. Effect of nutrients, hormones and serum on survival of rat islet β cells in culture. *Diabetologia* 37 (1), 15-21.
- Ling, Z., Kiekens, R., Mahler, T. et al., 1996. Effects of chronically elevated glucose levels on the functional properties of rat pancreatic β -cells. *Diabetes* 45 (12), 1774-1782.
- Ling, Z., Pipeleers, D. G., 1996. Prolonged exposure of human β cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. *J. Clin. Invest* 98 (12), 2805-2812.
- Ling, Z.C., Hong-Lie, C., Ostenson, C. G., Efendic, S., Khan, A., 2001. Hyperglycemia contributes to impaired insulin response in GK rat islets. *Diabetes* 50 Suppl 1, S108-S112.
- Lipson, K.L., Fonseca, S. G., Ishigaki, S. et al., 2006. Regulation of insulin biosynthesis in pancreatic beta cells by an endoplasmic reticulum-resident protein kinase IRE1. *Cell Metab* 4 (3), 245-254.
- Lipson, K.L., Ghosh, R., Urano, F., 2008. The role of IRE1 α in the degradation of insulin mRNA in pancreatic β -cells. *PLoS. ONE*. 3 (2), e1648.
- Liu, G., Sun, Y., Li, Z. et al., 2008. Apoptosis induced by endoplasmic reticulum stress involved in diabetic kidney disease. *Biochem. Biophys. Res. Commun*. 370 (4), 651-656.
- Liu, H., Remedi, M. S., Pappan, K. L. et al., 2009. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. *Diabetes* 58 (3), 663-672.
- Liu, K., Paterson, A. J., Chin, E., Kudlow, J. E., 2000. Glucose stimulates protein modification by *O*-linked GlcNAc in pancreatic β cells: linkage of *O*-linked GlcNAc to β cell death. *Proc. Natl. Acad. Sci. U. S. A* 97 (6), 2820-2825.
- Liu, Z., Stanojevic, V., Brindamour, L. J., Habener, J. F., 2012. GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β -cells from glucolipotoxicity. *J. Endocrinol*. 213 (2), 143-154.
- Longo, E.A., Tornheim, K., Deeney, J. T. et al., 1991. Oscillations in cytosolic free Ca^{2+} , oxygen consumption, and insulin secretion in glucose-stimulated rat pancreatic islets. *J Biol Chem* 266 (14), 9314-9319.
- Lortz, S., Gurgul-Convey, E., Lenzen, S., Tiedge, M., 2005. Importance of mitochondrial superoxide dismutase expression in insulin-producing cells for the toxicity of reactive oxygen species and proinflammatory cytokines. *Diabetologia* 48 (8), 1541-1548.

- Lortz, S., Tiedge, M., 2003. Sequential inactivation of reactive oxygen species by combined overexpression of SOD isoforms and catalase in insulin-producing cells. *Free Radic. Biol. Med.* 34 (6), 683-688.
- Lu, H., Koshkin, V., Allister, E. M., Gyulkhandanyan, A. V., Wheeler, M. B., 2010. Molecular and metabolic evidence for mitochondrial defects associated with β -cell dysfunction in a mouse model of type 2 diabetes. *Diabetes* 59 (2), 448-459.
- Lu, H., Yang, Y., Allister, E. M., Wijesekara, N., Wheeler, M. B., 2008. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach. *Mol. Cell Proteomics*. 7 (8), 1434-1451.
- Lu, M., Seufert, J., Habener, J. F., 1997. Pancreatic β -cell-specific repression of insulin gene transcription by CCAAT/enhancer-binding protein β . Inhibitory interactions with basic helix-loop-helix transcription factor E47. *J Biol Chem* 272 (45), 28349-28359.
- Lupi, R., Del Guerra, S., Tellini, C. et al., 1999. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. *Eur. J. Pharmacol.* 364, 205-209.
- Lupi, R., Mancarella, R., Del, G. S. et al., 2008. Effects of exendin-4 on islets from type 2 diabetes patients. *Diabetes Obes. Metab* 10 (6), 515-519.
- Ma, Y., Hendershot, L. M., 2004. Herp is dually regulated by both the endoplasmic reticulum stress-specific branch of the unfolded protein response and a branch that is shared with other cellular stress pathways. *J. Biol. Chem.* 279 (14), 13792-13799.
- Ma, Z., Portwood, N., Brodin, D., Grill, V., Bjorklund, A., 2007. Effects of diazoxide on gene expression in rat pancreatic islets are largely linked to elevated glucose and potentially serve to enhance β -cell sensitivity. *Diabetes* 56 (4), 1095-1106.
- MacDonald, M.J., 1981. High content of mitochondrial glycerol-3-phosphate dehydrogenase in pancreatic islets and its inhibition by diazoxide. *J. Biol. Chem.* 256 (16), 8287-8290.
- MacDonald, M.J., Fahien, L. A., Brown, L. J., Hasan, N. M., Buss, J. D., Kendrick, M. A., 2005. Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. *Am. J. Physiol Endocrinol. Metab* 288 (1), E1-15.
- MacDonald, M.J., Longacre, M. J., Langberg, E. C. et al., 2009. Decreased levels of metabolic enzymes in pancreatic islets of patients with type 2 diabetes. *Diabetologia* 52 (6), 1087-1091.
- Maechler, P., Jornot, L., Wollheim, C. B., 1999. Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic β cells. *J. Biol. Chem.* 274 (39), 27905-27913.
- Maedler, K., Carr, R. D., Bosco, D., Zuellig, R. A., Berney, T., Donath, M. Y., 2005. Sulfonylurea induced β -cell apoptosis in cultured human islets. *J. Clin. Endocrinol. Metab* 90 (1), 501-506.
- Maedler, K., Schumann, D. M., Schulthess, F. et al., 2006. Aging correlates with decreased β -cell proliferative capacity and enhanced sensitivity to apoptosis: a potential role for Fas and pancreatic duodenal homeobox-1. *Diabetes* 55 (9), 2455-2462.
- Maedler, K., Sergeev, P., Ris, F. et al., 2002. Glucose-induced β cell production of IL-1 β contributes to glucotoxicity in human pancreatic islets. *J. Clin. Invest* 110 (6), 851-860.
- Maedler, K., Spinas, G. A., Lehmann, R. et al., 2001. Glucose induces β -cell apoptosis via upregulation of the Fas receptor in human islets. *Diabetes* 50 (8), 1683-1690.

- Marchetti, P., Del, G. S., Marselli, L. et al., 2004. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. *J. Clin. Endocrinol. Metab* 89 (11), 5535-5541.
- Marchetti, P., Lupi, R., Del, G. S. et al., 2009. Goals of treatment for type 2 diabetes: β -cell preservation for glycemic control. *Diabetes Care* 32 Suppl 2, S178-S183.
- Marchetti, P., Lupi, R., Del, G. S., Bugliani, M., Marselli, L., Boggi, U., 2010. The β -cell in human type 2 diabetes. *Adv. Exp. Med. Biol.* 654, 501-514.
- Mariot, P., Gilon, P., Nenquin, M., Henquin, J. C., 1998. Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca^{2+} in β -cells. *Diabetes* 47 (3), 365-373.
- Marselli, L., Thorne, J., Dahiya, S. et al., 2010. Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. *PLoS One* 5 (7), e11499.
- Marshak, S., Leibowitz, G., Bertuzzi, F. et al., 1999. Impaired β -cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. *Diabetes* 48 (6), 1230-1236.
- Martens, G.A., Cai, Y., Hinke, S., Stange, G., Van de, C. M., Pipeleers, D., 2005. Glucose suppresses superoxide generation in metabolically responsive pancreatic β cells. *J. Biol. Chem.* in press, published online.
- Marzban, L., Tomas, A., Becker, T. C. et al., 2008. Small interfering RNA-mediated suppression of proislet amyloid polypeptide expression inhibits islet amyloid formation and enhances survival of human islets in culture. *Diabetes* 57 (11), 3045-3055.
- Masuyama, T., Komeda, K., Hara, A. et al., 2004. Chronological characterization of diabetes development in male Spontaneously Diabetic Torii rats. *Biochem. Biophys. Res. Commun.* 314 (3), 870-877.
- McGlasson, L., Best, L., Brown, P. D., 2011. The glucokinase activator GKA50 causes an increase in cell volume and activation of volume-regulated anion channels in rat pancreatic β -cells. *Mol. Cell Endocrinol.* 342 (1-2), 48-53.
- McKenzie, M.D., Jamieson, E., Jansen, E. S. et al., 2010. Glucose induces pancreatic islet cell apoptosis that requires the BH3-only proteins Bim and Puma and multi-BH domain protein Bax. *Diabetes* 59 (3), 644-652.
- Meghana, K., Sanjeev, G., Ramesh, B., 2007. Curcumin prevents streptozotocin-induced islet damage by scavenging free radicals: a prophylactic and protective role. *Eur. J. Pharmacol.* 577 (1-3), 183-191.
- Meininger, G.E., Scott, R., Alba, M. et al., 2011. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. *Diabetes Care* 34 (12), 2560-2566.
- Mellor, H., Parker, P. J., 1998. The extended protein kinase C superfamily. *Biochem. J.* 332 (Pt 2), 281-292.
- Miao, G., Ostrowski, R. P., Mace, J. et al., 2006. Dynamic production of hypoxia-inducible factor-1 α in early transplanted islets. *Am J Transplant.* 6 (11), 2636-2643.

- Miller, E.R., III, Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., Guallar, E., 2005. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann. Intern. Med.* 142 (1), 37-46.
- Minn, A.H., Pise-Masison, C. A., Radonovich, M. et al., 2005. Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. *Biochem Biophys Res Commun* 336 (3), 770-778.
- Miyazaki, Y., DeFronzo, R. A., 2008. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. *Diabetes Obes. Metab* 10 (12), 1204-1211.
- Miyazaki, Y., Matsuda, M., DeFronzo, R. A., 2002. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. *Diabetes Care* 25 (3), 517-523.
- Mizuno, A., Noma, Y., Kuwajima, M., Murakami, T., Zhu, M., Shima, K., 1999. Changes in islet capillary angioarchitecture coincide with impaired B-cell function but not with insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the diabetic phenotype at an advanced age. *Metabolism* 48 (4), 477-483.
- Modak, M.A., Parab, P. B., Ghaskadbi, S. S., 2009. Pancreatic islets are very poor in rectifying oxidative DNA damage. *Pancreas* 38 (1), 23-29.
- Montana, E., Bonner-Weir, S., Weir, G. C., 1993. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice. *J. Clin. Invest* 91 (3), 780-787.
- Moore, C.E., Omikorede, O., Gomez, E., Willars, G. B., Herbert, T. P., 2011. PERK activation at low glucose concentration is mediated by SERCA pump inhibition and confers preemptive cytoprotection to pancreatic β -cells. *Mol. Endocrinol.* 25 (2), 315-326.
- Moran, A., Zhang, H. J., Olson, L. K., Harmon, J. S., Poitout, V., Robertson, R. P., 1997. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. *J. Clin. Invest* 99 (3), 534-539.
- Morgan, D., Oliveira-Emilio, H. R., Keane, D. et al., 2007. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. *Diabetologia* 50 (2), 359-369.
- Moritz, W., Meier, F., Stroka, D. M. et al., 2002. Apoptosis in hypoxic human pancreatic islets correlates with HIF-1 α expression. *FASEB J* 16 (7), 745-747.
- Morse, E., Schroth, J., You, Y. H. et al., 2010. TRB3 is stimulated in diabetic kidneys, regulated by the ER stress marker CHOP, and is a suppressor of podocyte MCP-1. *Am. J. Physiol Renal Physiol* 299 (5), F965-F972.
- Mu, J., Petrov, A., Eiermann, G. J. et al., 2009. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. *Eur. J. Pharmacol.* 623 (1-3), 148-154.
- Mu, J., Woods, J., Zhou, Y. P. et al., 2006. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β -cell mass and function in a rodent model of type 2 diabetes. *Diabetes* 55 (6), 1695-1704.
- Nakamura, A., Terauchi, Y., Ohyama, S. et al., 2009. Impact of small-molecule glucokinase activator on glucose metabolism and β -cell mass. *Endocrinology* 150 (3), 1147-1154.

- Nakayama, M., Inoguchi, T., Sonta, T. et al., 2005. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. *Biochem. Biophys. Res. Commun.* 332 (4), 927-933.
- Nesher, R., Gross, D. J., Donath, M. Y., Cerasi, E., Kaiser, N., 1999. Interaction between genetic and dietary factors determines β -cell function in *Psammomys obesus*, an animal model of type 2 diabetes. *Diabetes* 48 (4), 731-737.
- Ng, S.F., Lin, R. C., Laybutt, D. R., Barres, R., Owens, J. A., Morris, M. J., 2010. Chronic high-fat diet in fathers programs β -cell dysfunction in female rat offspring. *Nature* 467 (7318), 963-966.
- Nielsen, D.A., Welsh, M., Casadaban, M. J., Steiner, D. F., 1985. Control of insulin gene expression in pancreatic β -cells and in an insulin-producing cell line, RIN-5F cells. I. Effects of glucose and cyclic AMP on the transcription of insulin mRNA. *J. Biol. Chem.* 260 (25), 13585-13589.
- Nissen, S.E., Wolski, K., 2010. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch. Intern. Med.* 170 (14), 1191-1201.
- Nonaka, A., Kiryu, J., Tsujikawa, A. et al., 2000. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. *Invest Ophthalmol. Vis. Sci.* 41 (9), 2702-2706.
- O'Brien, R.C., Luo, M., Balazs, N., Mercuri, J., 2000. In vitro and in vivo antioxidant properties of gliclazide. *J. Diabetes Complications* 14 (4), 201-206.
- Oberkofler, H., Hafner, M., Felder, T., Krempler, F., Patsch, W., 2009. Transcriptional co-activator peroxisome proliferator-activated receptor (PPAR) γ co-activator-1 β is involved in the regulation of glucose-stimulated insulin secretion in INS-1E cells. *J. Mol. Med.* 87 (3), 299-306.
- Olson, L.K., Qian, J., Poitout, V., 1998. Glucose rapidly and reversibly decreases INS-1 cell insulin gene transcription via decrements in STF-1 and C1 activator transcription factor activity. *Mol. Endocrinol.* 12 (2), 207-219.
- Olson, L.K., Redmon, J. B., Towle, H. C., Robertson, R. P., 1993. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. *J. Clin. Invest* 92 (1), 514-519.
- Olson, L.K., Sharma, A., Peshavaria, M. et al., 1995. Reduction of insulin gene transcription in HIT-T15 β cells chronically exposed to a supraphysiologic glucose concentration is associated with loss of STF-1 transcription factor expression. *Proc. Natl. Acad. Sci. U. S. A* 92 (20), 9127-9131.
- Ortis, F., Naamane, N., Flamez, D. et al., 2010. Cytokines interleukin-1 β and tumor necrosis factor- α regulate different transcriptional and alternative splicing networks in primary β -cells. *Diabetes* 59 (2), 358-374.
- Osowski, C.M., Urano, F., 2010. A switch from life to death in endoplasmic reticulum stressed β -cells. *Diabetes Obes. Metab* 12 Suppl 2, 58-65.
- Ostenson, C.G., Gaisano, H., Sheu, L., Tibell, A., Bartfai, T., 2006. Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients. *Diabetes* 55 (2), 435-440.
- Ovalle, F., Bell, D. S., 2004. Effect of rosiglitazone versus insulin on the pancreatic β -cell function of subjects with type 2 diabetes. *Diabetes Care* 27 (11), 2585-2589.

- Oyadomari, S., Mori, M., 2004. Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death. Differ.* 11 (4), 381-389.
- Pascal, S.M., Guiot, Y., Pelengaris, S., Khan, M., Jonas, J. C., 2008. Effects of c-MYC activation on glucose stimulus-secretion coupling events in mouse pancreatic islets. *Am J Physiol Endocrinol Metab* 295 (1), E92-E102.
- Pascal, S.M., Veiga-da-Cunha, M., Gilon, P., Van Schaftingen, E., Jonas, J. C., 2010. Effects of fructosamine-3-kinase deficiency on function and survival of mouse pancreatic islets after prolonged culture in high glucose or ribose concentrations. *Am J Physiol Endocrinol Metab* 298 (3), E586-E596.
- Patane, G., Piro, S., Rabuazzo, A. M., Anello, M., Vigneri, R., Purrello, F., 2000. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic β -cells. *Diabetes* 49 (5), 735-740.
- Pazdro, R., Burgess, J. R., 2010. The role of vitamin E and oxidative stress in diabetes complications. *Mech. Ageing Dev.* 131 (4), 276-286.
- Pelengaris, S., Khan, M., Evan, G. I., 2002. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *Cell* 109 (3), 321-334.
- Perfetti, R., Zhou, J., Doyle, M. E., Egan, J. M., 2000. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. *Endocrinology* 141 (12), 4600-4605.
- Permutt, M.A., 1974. Effect of glucose on initiation and elongation rates in isolated rat pancreatic islets. *J. Biol. Chem.* 249 (9), 2738-2742.
- Pi, J., Zhang, Q., Fu, J. et al., 2010. ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. *Toxicol. Appl. Pharmacol.* 244 (1), 77-83.
- Pick, A., Clark, J., Kubstrup, C. et al., 1998. Role of apoptosis in failure of β -cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. *Diabetes* 47 (3), 358-364.
- Pino, M.F., Ye, D. Z., Linning, K. D. et al., 2005. Elevated glucose attenuates human insulin gene promoter activity in INS-1 pancreatic β -cells via reduced nuclear factor binding to the A5/core and Z element. *Mol. Endocrinol.* 19 (5), 1343-1360.
- Piro, S., Anello, M., Di Pietro, C. et al., 2002. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. *Metabolism* 51 (10), 1340-1347.
- Pirot, P., Naamane, N., Libert, F. et al., 2007. Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs. *Diabetologia* 50 (5), 1006-1014.
- Poitout, V., Amyot, J., Semache, M., Zarrouki, B., Hagman, D., Fontes, G., 2010. Glucolipotoxicity of the pancreatic β cell. *Biochim. Biophys. Acta* 1801 (3), 289-298.
- Poitout, V., Olson, L. K., Robertson, R. P., 1996. Chronic exposure of β TC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. *J. Clin. Invest* 97 (4), 1041-1046.
- Poitout, V., Robertson, R. P., 2008. Glucolipotoxicity: fuel excess and β -cell dysfunction. *Endocr. Rev.* 29 (3), 351-366.

- Pospisilik, J.A., Martin, J., Doty, T. et al., 2003. Dipeptidyl peptidase IV inhibitor treatment stimulates β -cell survival and islet neogenesis in streptozotocin-induced diabetic rats. *Diabetes* 52 (3), 741-750.
- Puddu, A., Storace, D., Odetti, P., Viviani, G. L., 2010. Advanced glycation end-products affect transcription factors regulating insulin gene expression. *Biochem. Biophys. Res. Commun.* 395 (1), 122-125.
- Puri, S., Cano, D. A., Hebrok, M., 2009. A Role for von Hippel-Lindau Protein in Pancreatic β -Cell Function. *Diabetes* 58 (2), 433-441.
- Qian, B., Wang, H., Men, X. et al., 2008. TRIB3 is implicated in glucotoxicity- and ER-stress-induced β -cell apoptosis. *J Endocrinol* 199 (3), 407-416.
- Quintens, R., Hendrickx, N., Lemaire, K., Schuit, F., 2008. Why expression of some genes is disallowed in β -cells. *Biochem Soc. Trans.* 36 (Pt 3), 300-305.
- Qvigstad, E., Kollind, M., Grill, V., 2004. Nine weeks of bedtime diazoxide is well tolerated and improves β -cell function in subjects with Type 2 diabetes. *Diabet. Med.* 21 (1), 73-76.
- Radtke, M., Kollind, M., Qvigstad, E., Grill, V., 2007. Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. *Diabet. Med.* 24 (2), 172-177.
- Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., Henquin, J. C., 2008. Pancreatic β -cell mass in European subjects with type 2 diabetes. *Diabetes Obes. Metab* 10 Suppl 4, 32-42.
- Ravier, M.A., Daro, D., Roma, L. P. et al., 2011. Mechanisms of control of the free Ca^{2+} concentration in the endoplasmic reticulum of mouse pancreatic β -cells: interplay with cell metabolism and $[\text{Ca}^{2+}]_c$ and role of SERCA2b and SERCA3. *Diabetes* 60 (10), 2533-2545.
- Ritzel, R.A., Hansen, J. B., Veldhuis, J. D., Butler, P. C., 2004. Induction of β -cell rest by a Kir6.2/SUR1-selective K_{ATP} -channel opener preserves β -cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose. *J. Clin. Endocrinol. Metab* 89 (2), 795-805.
- Rivera, J.F., Gurlo, T., Daval, M. et al., 2011. Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic β -cells: protective role of p62-positive cytoplasmic inclusions. *Cell Death. Differ.* 18 (3), 415-426.
- Robertson, R.P., 2004. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β cells in diabetes. *J. Biol. Chem.* 279 (41), 42351-42354.
- Robertson, R.P., 2009. β -cell deterioration during diabetes: what's in the gun? *Trends Endocrinol. Metab* 20 (8), 388-393.
- Robertson, R.P., Harmon, J., Tran, P. O., Tanaka, Y., Takahashi, H., 2003. Glucose toxicity in β -cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. *Diabetes* 52 (3), 581-587.
- Robertson, R.P., Harmon, J. S., 2006. Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet β cell. *Free Radic. Biol. Med.* 41 (2), 177-184.
- Robertson, R.P., Olson, L. K., Zhang, H. J., 1994. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. *Diabetes* 43 (9), 1085-1089.

- Robertson, R.P., Zhang, H. J., Pyzdrowski, K. L., Walseth, T. F., 1992. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. *J Clin Invest* 90 (2), 320-325.
- Roche, E., Assimacopoulos-Jeannet, F., Witters, L. A. et al., 1997. Induction by glucose of genes coding for glycolytic enzymes in a pancreatic β -cell line (INS-1). *J. Biol. Chem.* 272 (5), 3091-3098.
- Roma, L.P., Duprez, J., Takahashi, H. K., Gilon, P., Wiederkehr, A., Jonas, J. C., 2012. Dynamic measurements of mitochondrial hydrogen peroxide concentration and glutathione redox state in rat pancreatic β -cells using ratiometric fluorescent proteins: confounding effects of pH with HyPer but not roGFP1. *Biochem. J.* 441 (3), 971-978.
- Rossetti, L., Shulman, G. I., Zawulich, W., DeFronzo, R. A., 1987. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. *J. Clin. Invest* 80 (4), 1037-1044.
- Ryan, E.A., Imes, S., Wallace, C., 2004. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. *Diabetes Care* 27 (5), 1028-1032.
- Sakai, K., Matsumoto, K., Nishikawa, T. et al., 2003. Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic β -cells. *Biochem. Biophys. Res. Commun.* 300 (1), 216-222.
- Sako, Y., Grill, V. E., 1990. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. *Diabetes* 39 (12), 1580-1583.
- Sakuraba, H., Mizukami, H., Yagihashi, N., Wada, R., Hanyu, C., Yagihashi, S., 2002. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. *Diabetologia* 45 (1), 85-96.
- Sandu, O., Song, K., Cai, W., Zheng, F., Uribarri, J., Vlassara, H., 2005. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. *Diabetes* 54 (8), 2314-2319.
- Sargsyan, E., Ortsater, H., Thorn, K., Bergsten, P., 2008. Diazoxide-induced β -cell rest reduces endoplasmic reticulum stress in lipotoxic β -cells. *J. Endocrinol.* 199 (1), 41-50.
- Sarre, A., Gabrielli, J., Vial, G., Leverve, X. M., Assimacopoulos-Jeannet, F., 2012. Reactive oxygen species are produced at low glucose and contribute to the activation of AMPK in insulin-secreting cells. *Free Radic. Biol. Med.* 52 (1), 142-150.
- Sato, Y., Endo, H., Okuyama, H. et al., 2011. Cellular hypoxia of pancreatic β -cells due to high levels of oxygen consumption for insulin secretion *in vitro*. *J. Biol. Chem.*
- Scherbaum, W.A., Schweizer, A., Mari, A. et al., 2008. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. *Diabetes Obes. Metab* 10 (11), 1114-1124.
- Scheuner, D., Kaufman, R. J., 2008. The unfolded protein response: a pathway that links insulin demand with β -cell failure and diabetes. *Endocr. Rev.* 29 (3), 317-333.
- Schmitz-Peiffer, C., Laybutt, D. R., Burchfield, J. G. et al., 2007. Inhibition of PKC ϵ improves glucose-stimulated insulin secretion and reduces insulin clearance. *Cell Metab* 6 (4), 320-328.

- Schroder, M., 2008. Endoplasmic reticulum stress responses. *Cell Mol. Life Sci.* 65 (6), 862-894.
- Schroder, M., Kaufman, R. J., 2005. ER stress and the unfolded protein response. *Mutat. Res.* 569 (1-2), 29-63.
- Schuit, F., Flamez, D., De Vos, A., Pipeleers, D., 2002. Glucose-regulated gene expression maintaining the glucose-responsive state of β -cells. *Diabetes* 51 Suppl 3, S326-S332.
- Schuit, F.C., In't Veld, P. A., Pipeleers, D. G., 1988. Glucose stimulates proinsulin biosynthesis by a dose-dependent recruitment of pancreatic beta cells. *Proc. Natl. Acad. Sci. U. S A* 85 (11), 3865-3869.
- Scorrano, L., Oakes, S. A., Opferman, J. T. et al., 2003. BAX and BAK regulation of endoplasmic reticulum Ca^{2+} : a control point for apoptosis. *Science* 300 (5616), 135-139.
- Sefi, M., Fetoui, H., Lachkar, N. et al., 2011. Centaurium erythraea (Gentianaceae) leaf extract alleviates streptozotocin-induced oxidative stress and β -cell damage in rat pancreas. *J. Ethnopharmacol.* 135 (2), 243-250.
- Seino, S., Takahashi, H., Takahashi, T., Shibasaki, T., 2012. Treating diabetes today: a matter of selectivity of sulphonylureas. *Diabetes Obes. Metab* 14 Suppl 1, 9-13.
- Semenza, G.L., 2010. Oxygen homeostasis. *Wiley. Interdiscip. Rev. Syst. Biol. Med.* 2 (3), 336-361.
- Sempoux, C., Guiot, Y., Dubois, D., Moulin, P., Rahier, J., 2001. Human type 2 diabetes: morphological evidence for abnormal β -cell function. *Diabetes* 50 Suppl 1, S172-S177.
- Senee, V., Vatter, K. M., Delepine, M. et al., 2004. Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. *Diabetes* 53 (7), 1876-1883.
- Seo, H.Y., Kim, Y. D., Lee, K. M. et al., 2008. Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner. *Endocrinology* 149 (8), 3832-3841.
- Setter, S.M., Iltz, J. L., Thams, J., Campbell, R. K., 2003. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. *Clin. Ther.* 25 (12), 2991-3026.
- Seufert, J., Urquhart, R., 2008. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. *Diabetes Res. Clin. Pract.* 79 (3), 453-460.
- Seufert, J., Weir, G. C., Habener, J. F., 1998. Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein β and transactivator islet duodenum homeobox-1 in rat pancreatic β cells during the development of diabetes mellitus. *J Clin Invest* 101 (11), 2528-2539.
- Shalev, A., Pise-Masison, C. A., Radonovich, M. et al., 2002. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGF β signaling pathway. *Endocrinology* 143 (9), 3695-3698.
- Shankar, R.R., Zhu, J. S., Baron, A. D., 1998. Glucosamine infusion in rats mimics the β -cell dysfunction of non-insulin-dependent diabetes mellitus. *Metabolism* 47, 573-577.

- Shao, J.Q., Iwashita, N., Du, H. et al., 2007. Angiotensin II receptor blocker provides pancreatic β -cell protection independent of blood pressure lowering in diabetic db/db mice. *Acta Pharmacol. Sin.* 28 (2), 246-257.
- Shao, W., Yu, Z., Fantus, I. G., Jin, T., 2010. Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic β -cells. *Cell Signal.* 22 (8), 1240-1246.
- Sharma, A., Olson, L. K., Robertson, R. P., Stein, R., 1995. The reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to high glucose concentration is associated with the loss of RIPE3b1 and STF-1 transcription factor expression. *Mol. Endocrinol.* 9 (9), 1127-1134.
- Shoelson, S.E., Lee, J., Goldfine, A. B., 2006. Inflammation and insulin resistance. *J. Clin. Invest* 116 (7), 1793-1801.
- Skelly, R.H., Schuppin, G. T., Ishihara, H., Oka, Y., Rhodes, C. J., 1996. Glucose-regulated translational control of proinsulin biosynthesis with that of the proinsulin endopeptidases PC2 and PC3 in the insulin-producing MIN6 cell line. *Diabetes* 45 (1), 37-43.
- Smith, S.A., Lister, C. A., Toseland, C. D., Buckingham, R. E., 2000. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. *Diabetes Obes. Metab* 2 (6), 363-372.
- Smith, S.A., Porter, L. E., Biswas, N., Freed, M. I., 2004. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. *J. Clin. Endocrinol. Metab* 89 (12), 6048-6053.
- Son, S.M., 2007. Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes. *Diabetes Res. Clin. Pract.* 77 Suppl 1, S65-S70.
- Song, B., Scheuner, D., Ron, D., Pennathur, S., Kaufman, R. J., 2008. Chop deletion reduces oxidative stress, improves β cell function, and promotes cell survival in multiple mouse models of diabetes. *J Clin Invest* 118 (10), 3378-3389.
- Song, D., Hutchings, S., Pang, C. C., 2005. Chronic N-acetylcysteine prevents fructose-induced insulin resistance and hypertension in rats. *Eur. J. Pharmacol.* 508 (1-3), 205-210.
- Song, S.H., Rhodes, C. J., Veldhuis, J. D., Butler, P. C., 2003. Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. *Endocrinology* 144 (8), 3399-3405.
- Spacek, T., Santorova, J., Zacharovova, K. et al., 2008. Glucose-stimulated insulin secretion of insulinoma INS-1E cells is associated with elevation of both respiration and mitochondrial membrane potential. *Int. J. Biochem. Cell Biol.* 40 (8), 1522-1535.
- Srinivasan, S., Bernal-Mizrachi, E., Ohsugi, M., Permutt, M. A., 2002. Glucose promotes pancreatic islet β -cell survival through a PI 3-kinase/Akt-signaling pathway. *Am J Physiol Endocrinol Metab* 283 (4), E784-E793.
- Steil, G.M., Trivedi, N., Jonas, J. C. et al., 2001. Adaptation of β -cell mass to substrate oversupply: enhanced function with normal gene expression. *Am. J. Physiol Endocrinol. Metab* 280 (5), E788-E796.
- Stranges, S., Marshall, J. R., Natarajan, R. et al., 2007. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. *Ann. Intern. Med.* 147 (4), 217-223.

- Suzuki, C.K., Bonifacino, J. S., Lin, A. Y., Davis, M. M., Klausner, R. D., 1991. Regulating the retention of T-cell receptor α chain variants within the endoplasmic reticulum: Ca^{2+} -dependent association with BiP. *J. Cell Biol.* 114 (2), 189-205.
- Suzuki, M., Honda, K., Fukazawa, M. et al., 2012. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. *J. Pharmacol. Exp. Ther.* 341 (3), 692-701.
- Svensson, A.M., Ostenson, C. G., Bodin, B., Jansson, L., 2005. Lack of compensatory increase in islet blood flow and islet mass in GK rats following 60% partial pancreatectomy. *J. Endocrinol.* 184 (2), 319-327.
- Svensson, A.M., Ostenson, C. G., Jansson, L., 2000. Age-induced changes in pancreatic islet blood flow: evidence for an impaired regulation in diabetic GK rats. *Am. J. Physiol Endocrinol. Metab* 279 (5), E1139-E1144.
- Sweet, I.R., Gilbert, M., 2006. Contribution of calcium influx in mediating glucose-stimulated oxygen consumption in pancreatic islets. *Diabetes* 55 (12), 3509-3519.
- Swenne, I., 1982. The role of glucose in the in vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic β -cells. *Diabetes* 31 (9), 754-760.
- Tajiri, Y., Grill, V., 2000. Aminoguanidine exerts a β -cell function-preserving effect in high glucose-cultured beta-cells (INS-1). *Int. J. Exp. Diabetes Res.* 1 (2), 111-119.
- Tajiri, Y., Moller, C., Grill, V., 1997. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. *Endocrinology* 138 (1), 273-280.
- Takatori, A., Ishii, Y., Itagaki, S., Kyuwa, S., Yoshikawa, Y., 2004. Amelioration of the β -cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments. *Diabetes Metab Res. Rev.* 20 (3), 211-218.
- Takehiro, M., Fujimoto, S., Shimodahira, M. et al., 2005. Chronic exposure to β -hydroxybutyrate inhibits glucose-induced insulin release from pancreatic islets by decreasing NADH contents. *Am. J. Physiol Endocrinol. Metab* 288 (2), E372-E380.
- Tanaka, Y., Gleason, C. E., Tran, P. O., Harmon, J. S., Robertson, R. P., 1999. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. *Proc. Natl. Acad. Sci. U. S. A* 96 (19), 10857-10862.
- Tanaka, Y., Tran, P. O., Harmon, J., Robertson, R. P., 2002. A role for glutathione peroxidase in protecting pancreatic β cells against oxidative stress in a model of glucose toxicity. *Proc. Natl. Acad. Sci. U. S. A* 99 (19), 12363-12368.
- Tang, C., Han, P., Oprescu, A. I. et al., 2007. Evidence for a role of superoxide generation in glucose-induced β -cell dysfunction in vivo. *Diabetes* 56 (11), 2722-2731.
- Tang, C., Koulajian, K., Schuiki, I. et al., 2012. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. *Diabetologia* 55 (5), 1366-1379.
- Taylor, C.T., 2008. Mitochondria and cellular oxygen sensing in the HIF pathway. *Biochem. J.* 409 (1), 19-26.
- Tengholm, A., Hellman, B., Gylfe, E., 1999. Glucose regulation of free Ca^{2+} in the endoplasmic reticulum of mouse pancreatic β cells. *J. Biol. Chem.* 274 (52), 36883-36890.

- Thameem, F., Farook, V. S., Bogardus, C., Prochazka, M., 2006. Association of amino acid variants in the activating transcription factor 6 gene (ATF6) on 1q21-q23 with type 2 diabetes in Pima Indians. *Diabetes* 55 (3), 839-842.
- Thorens, B., Wu, Y. J., Leahy, J. L., Weir, G. C., 1992. The loss of GLUT2 expression by glucose-unresponsive β cells of db/db mice is reversible and is induced by the diabetic environment. *J. Clin. Invest* 90 (1), 77-85.
- Tian, Y.A., Johnson, G., Ashcroft, S. J., 1998. Sulfonylureas enhance exocytosis from pancreatic β -cells by a mechanism that does not involve direct activation of protein kinase C. *Diabetes* 47 (11), 1722-1726.
- Tiedge, M., Lortz, S., Drinkgern, J., Lenzen, S., 1997. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. *Diabetes* 46 (11), 1733-1742.
- Tillmar, L., Carlsson, C., Welsh, N., 2002. Control of insulin mRNA stability in rat pancreatic islets. Regulatory role of a 3'-untranslated region pyrimidine-rich sequence. *J. Biol. Chem.* 277 (2), 1099-1106.
- Tobiasch, E., Gunther, L., Bach, F. H., 2001. Heme oxygenase-1 protects pancreatic β cells from apoptosis caused by various stimuli. *J. Investig. Med.* 49 (6), 566-571.
- Tokuyama, Y., Sturis, J., DePaoli, A. M. et al., 1995. Evolution of β -cell dysfunction in the male Zucker diabetic fatty rat. *Diabetes* 44 (12), 1447-1457.
- Tonooka, N., Oseid, E., Zhou, H., Harmon, J. S., Robertson, R. P., 2007. Glutathione peroxidase protein expression and activity in human islets isolated for transplantation. *Clin. Transplant.* 21 (6), 767-772.
- Topp, B.G., McArthur, M. D., Finegood, D. T., 2004. Metabolic adaptations to chronic glucose infusion in rats. *Diabetologia* 47 (9), 1602-1610.
- Trinh, K., Minassian, C., Lange, A. J., O'Doherty, R. M., Newgard, C. B., 1997. Adenovirus-mediated expression of the catalytic subunit of glucose-6-phosphatase in INS-1 cells. Effects on glucose cycling, glucose usage, and insulin secretion. *J. Biol. Chem.* 272 (40), 24837-24842.
- Tsujimoto, Y., Shimizu, S., 2007. Role of the mitochondrial membrane permeability transition in cell death. *Apoptosis.* 12 (5), 835-840.
- Turner, R.C., 1998. The U.K. Prospective Diabetes Study. A review. *Diabetes Care* 21 Suppl 3, C35-C38.
- Turner, R.C., McCarthy, S. T., Holman, R. R., Harris, E., 1976. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. *Br. Med. J.* 1 (6020), 1252-1254.
- Turrens, J.F., 2003. Mitochondrial formation of reactive oxygen species. *J. Physiol* 552 (Pt 2), 335-344.
- Tyrberg, B., Eizirik, D. L., Hellerstrom, C., Pipeleers, D. G., Andersson, A., 1996. Human pancreatic β -cell deoxyribonucleic acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. *Endocrinology* 137 (12), 5694-5699.
- UKPDS, U.K.P.D.S.G., 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 352 (9131), 854-865.

- Unger, R.H., Grundy, S., 1985. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. *Diabetologia* 28 (3), 119-121.
- Van de Casteele, M., Kefas, B. A., Cai, Y. et al., 2003. Prolonged culture in low glucose induces apoptosis of rat pancreatic β -cells through induction of c-myc. *Biochem. Biophys. Res. Commun.* 312 (4), 937-944.
- Van Lommel, L., Janssens, K., Quintens, R. et al., 2006. Probe-independent and direct quantification of insulin mRNA and growth hormone mRNA in enriched cell preparations. *Diabetes* 55 (12), 3214-3220.
- Vander Mierde, D., Scheuner, D., Quintens, R. et al., 2007. Glucose activates a protein phosphatase-1-mediated signaling pathway to enhance overall translation in pancreatic β -cells. *Endocrinology* 148 (2), 609-617.
- Varadi, A., Rutter, G. A., 2002. Dynamic imaging of endoplasmic reticulum Ca^{2+} concentration in insulin-secreting MIN6 Cells using recombinant targeted cameleons: roles of sarco(endo)plasmic reticulum Ca^{2+} -ATPase (SERCA)-2 and ryanodine receptors. *Diabetes* 51 Suppl 1, S190-S201.
- Volkmar, M., Dedeurwaerder, S., Cunha, D. A. et al., 2012. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. *EMBO J.* 31 (6), 1405-1426.
- Waanders, L.F., Chwalek, K., Monetti, M., Kumar, C., Lammert, E., Mann, M., 2009. Quantitative proteomic analysis of single pancreatic islets. *Proc Natl Acad Sci U. S A* 106 (45), 18902-18907.
- Wajchenberg, B.L., 2007. β -cell failure in diabetes and preservation by clinical treatment. *Endocr. Rev.* 28 (2), 187-218.
- Wallace, T.M., Levy, J. C., Matthews, D. R., 2004. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. *Diabet. Med.* 21 (6), 568-576.
- Wang, H., Kouri, G., Wollheim, C. B., 2005a. ER stress and SREBP-1 activation are implicated in β -cell glucolipotoxicity. *J. Cell Sci.* 118 (Pt 17), 3905-3915.
- Wang, J., Shen, L., Najafi, H. et al., 1997. Regulation of insulin preRNA splicing by glucose. *Proc. Natl. Acad. Sci. U. S. A* 94 (9), 4360-4365.
- Wang, W., Upshaw, L., Strong, D. M., Robertson, R. P., Reems, J., 2005b. Increased oxygen consumption rates in response to high glucose detected by a novel oxygen biosensor system in non-human primate and human islets. *J. Endocrinol.* 185 (3), 445-455.
- Wei, P., Shi, M., Barnum, S., Cho, H., Carlson, T., Fraser, J. D., 2009. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells. *Diabetologia* 52 (10), 2142-2150.
- Weir, G.C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S., Sharma, A., 2001. β -cell adaptation and decompensation during the progression of diabetes. *Diabetes* 50 Suppl 1, S154-S159.
- Weir, G.C., Marselli, L., Marchetti, P., Katsuta, H., Jung, M. H., Bonner-Weir, S., 2009. Towards better understanding of the contributions of overwork and glucotoxicity to the β -cell inadequacy of type 2 diabetes. *Diabetes Obesity & Metabolism* 11, 82-90.

- Welsh, M., Nielsen, D. A., MacKrell, A. J., Steiner, D. F., 1985. Control of insulin gene expression in pancreatic β -cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability. *J. Biol. Chem.* 260 (25), 13590-13594.
- Welsh, M., Scherberg, N., Gilmore, R., Steiner, D. F., 1986. Translational control of insulin biosynthesis. Evidence for regulation of elongation, initiation and signal-recognition-particle-mediated translational arrest by glucose. *Biochem. J.* 235 (2), 459-467.
- Welsh, N., Cnop, M., Kharroubi, I. et al., 2005. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? *Diabetes* 54 (11), 3238-3244.
- Wice, B.M., Bernal-Mizrachi, E., Permutt, M. A., 2001. Glucose and other insulin secretagogues induce, rather than inhibit, expression of *Id-1* and *Id-3* in pancreatic islet beta cells. *Diabetologia* 44 (4), 453-463.
- Wicksteed, B., Alarcon, C., Briaud, I., Lingohr, M. K., Rhodes, C. J., 2003. Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet β -cells but not regulated via a positive feedback of secreted insulin. *J. Biol. Chem.* 278 (43), 42080-42090.
- Wicksteed, B., Herbert, T. P., Alarcon, C., Lingohr, M. K., Moss, L. G., Rhodes, C. J., 2001. Cooperativity between the preproinsulin mRNA untranslated regions is necessary for glucose-stimulated translation. *J. Biol. Chem.* 276 (25), 22553-22558.
- Wiesener, M.S., Jurgensen, J. S., Rosenberger, C. et al., 2003. Widespread hypoxia-inducible expression of HIF-2 α in distinct cell populations of different organs. *FASEB J.* 17 (2), 271-273.
- Wilding, J.P., Norwood, P., T'joen, C., Bastien, A., List, J. F., Fiedorek, F. T., 2009. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. *Diabetes Care* 32 (9), 1656-1662.
- Wolf, G., Aumann, N., Michalska, M. et al., 2010. Peroxiredoxin III protects pancreatic β cells from apoptosis. *J. Endocrinol.* 207 (2), 163-175.
- Xiang, A.H., Peters, R. K., Kjos, S. L. et al., 2006. Effect of pioglitazone on pancreatic β -cell function and diabetes risk in Hispanic women with prior gestational diabetes. *Diabetes* 55 (2), 517-522.
- Xu, G., Stoffers, D. A., Habener, J. F., Bonner-Weir, S., 1999. Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 48 (12), 2270-2276.
- Yajima, K., Hirose, H., Fujita, H. et al., 2003. Combination therapy with PPAR γ and PPAR α agonists increases glucose-stimulated insulin secretion in *db/db* mice. *Am. J. Physiol Endocrinol. Metab* 284 (5), E966-E971.
- Yakes, F.M., Van, H. B., 1997. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. *Proc. Natl. Acad. Sci. U. S. A* 94 (2), 514-519.
- Yamamoto, K., Uchida, S., Kitano, K. et al., 2011. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. *Br. J. Pharmacol.* 164 (1), 181-191.

- Yan, L.J., Levine, R. L., Sohal, R. S., 1997. Oxidative damage during aging targets mitochondrial aconitase. *Proc. Natl. Acad. Sci. U. S. A* 94 (21), 11168-11172.
- Yan, L.J., Sohal, R. S., 1998. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. *Proc. Natl. Acad. Sci. U. S. A* 95 (22), 12896-12901.
- Yki-Jarvinen, H., 2004. Thiazolidinediones. *N. Engl. J. Med.* 351 (11), 1106-1118.
- Yki-Jarvinen, H., Esko, N., Eero, H., Marja-Riitta, T., 1988. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. *Am. J. Med.* 84 (2), 185-192.
- Yoon, K.H., Ko, S. H., Cho, J. H. et al., 2003. Selective β -cell loss and α -cell expansion in patients with type 2 diabetes mellitus in Korea. *Journal of Clinical Endocrinology and Metabolism* 88 (5), 2300-2308.
- Yoshikawa, H., Ma, Z., Bjorklund, A., Grill, V., 2004. Short-term intermittent exposure to diazoxide improves functional performance of β -cells in a high-glucose environment. *Am. J. Physiol Endocrinol. Metab* 287 (6), E1202-E1208.
- Yoshikawa, H., Tajiri, Y., Sako, Y., Hashimoto, T., Umeda, F., Nawata, H., 2002. Glucosamine-induced β -cell dysfunction: a possible involvement of glucokinase or glucose-transporter type 2. *Pancreas* 24 (3), 228-234.
- Young, A.A., Gedulin, B. R., Bhavsar, S. et al., 1999. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (*ob/ob*, *db/db*) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (*Macaca mulatta*). *Diabetes* 48 (5), 1026-1034.
- Zambrowicz, B., Freiman, J., Brown, P. M. et al., 2012. LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial. *Clin. Pharmacol. Ther.* 92 (2), 158-169.
- Zangen, D.H., Bonner-Weir, S., Lee, C. H. et al., 1997. Reduced insulin, GLUT2, and IDX-1 in beta-cells after partial pancreatectomy. *Diabetes* 46 (2), 258-264.
- Zeender, E., Maedler, K., Bosco, D., Berney, T., Donath, M. Y., Halban, P. A., 2004. Pioglitazone and sodium salicylate protect human β -cells against apoptosis and impaired function induced by glucose and interleukin-1 β . *J. Clin. Endocrinol. Metab* 89 (10), 5059-5066.
- Zehetner, J., Danzer, C., Collins, S. et al., 2008. pVHL is a regulator of glucose metabolism and insulin secretion in pancreatic β cells. *Genes Dev.* 22 (22), 3135-3146.
- Zhang, C.Y., Baffy, G., Perret, P. et al., 2001. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, β cell dysfunction, and type 2 diabetes. *Cell* 105 (6), 745-755.
- Zhang, L., Lai, E., Teodoro, T., Volchuk, A., 2009. GRP78, but Not Protein-disulfide Isomerase, Partially Reverses Hyperglycemia-induced Inhibition of Insulin Synthesis and Secretion in Pancreatic β -Cells. *J. Biol. Chem.* 284 (8), 5289-5298.
- Zhang, W., Khan, A., Ostenson, C. G., Berggren, P. O., Efendic, S., Meister, B., 2002. Down-regulated expression of exocytotic proteins in pancreatic islets of diabetic GK rats. *Biochem. Biophys. Res. Commun.* 291 (4), 1038-1044.
- Zhang, Z., Liew, C. W., Handy, D. E. et al., 2010. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and β -cell apoptosis. *FASEB J* 24 (5), 1497-1505.

- Zhao, Z., Zhao, C., Zhang, X. H. et al., 2009. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. *Endocrinology* 150 (6), 2569-2576.
- Zhou, Y.P., Grill, V., 1995. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. *J. Clin. Endocrinol. Metab* 80 (5), 1584-1590.
- Zhou, Y.P., Marlen, K., Palma, J. F. et al., 2003. Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? *J. Biol. Chem.* 278 (51), 51316-51323.
- Zhu, Y., Shu, T., Lin, Y. et al., 2011. Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic β -cells. *Biochem. Biophys. Res. Commun.* 404 (1), 159-165.
- Zraika, S., Aston-Mourney, K., Laybutt, D. R. et al., 2006. The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. *Diabetologia* 49 (6), 1254-1263.
- Zraika, S., Hull, R. L., Verchere, C. B. et al., 2010. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? *Diabetologia* 53 (6), 1046-1056.